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ABSTRACT
Background: Despite the improved screening and treatment modalities, lung
cancer is the second leading cause of cancer and accounts for 27% of all cancer deaths in
the United States. Survivors of lung cancer experience physical, social, and particularly
psychological challenges. Lung cancer stigma is a formidable challenge for survivors of
lung cancer that complicates their physical, psychological and social well-being.
The Cataldo Lung Cancer Stigma Scale is the first instrument adapted to measure
lung cancer stigma. This instrument was adapted from Berger’s HIV Stigma Scale. HIV
stigma and lung cancer stigma share similarities. These health-related stigmas reflect
behaviors that are associated with the development of a debilitating disease and where
those who partake in this behavior bear responsibility for the development of the disease.
In previous studies, the CLCSS was reported to have very good reliability and construct
validity. However, those studies lacked adequate African American representation.
African Americans experience a significant disparity in lung cancer incidence and
survival rates. In South Carolina, African American men have a higher incidence and
lower survival rate in comparison to their Caucasian counterparts, whereas African
American women have a lower incidence and lower survival rate compared to Caucasian
women. This disparity is concerning and warrants investigation of the possible factors
that contribute to the disparate rate. The goal of this research is to enhance existing
knowledge of stigma and its effect on individuals in South Carolina living with a lung

vi

cancer diagnosis with equal representation of African American and Caucasian survivors
of lung cancer.
Methods: This multiple-method study evaluated the reliability and construct
validity of the CLCSS among a purposive sample of survivors of lung cancer in South
Carolina. Secondly, lung cancer stigma, depression, and QOL were evaluated by the
calculation and comparison of means among demographic characteristics. Thirdly, the
relationship between lung cancer stigma and race was evaluated, adjusting for
demographic characteristics. And lastly, the experience of living with lung cancer and the
interpretation of the CLCSS were explored among African American participants.
Findings: Participants (n = 56) included 30 Caucasian and 26 African American
survivors of lung cancer recruited from a cancer registry of an American College of
Surgeons–accredited program, a support club for survivors of lung cancer, and a private
ambulatory oncology practice, all near Columbia, South Carolina. Among the 26 African
American participants, quantitative analysis indicated a moderate level of lung cancer
stigma, a moderately high level of depressive symptoms, and quality of life (QOL).
Depressive symptoms were positively associated to lung cancer stigma, and QOL was
negatively associated to lung cancer stigma. Qualitative analysis revealed social isolation
secondary to physical limitations, regrets relative to cigarette smoking, and unfair
treatment of insurance providers and employers.
Conclusions: Lung cancer stigma adversely impacts overall QOL of survivors of
lung cancer. It is imperative that health professionals acknowledge and are aware of the
negative influences lung cancer stigma imposes. A holistic clinical evaluation
encompassing physical, psychological, and social well-being is needed to identify and

vii

address the needs of survivors of lung cancer relative to lung cancer stigma and the
impact it may have on overall QOL. Additional research is needed to assist with the
development of tailored interventions that will aid in mitigating the harmful effects of
lung cancer stigma.
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CHAPTER 1: INTRODUCTION
History and Overview of Lung Cancer
Lung cancer is the second-leading cause of cancer and accounts for 27% of all
cancer deaths in the United States (American Cancer Society [ACS], 2019; American
Lung Association [ALA], 2019). The ACS estimated over 225,000 new cases of lung
cancer would be diagnosed in 2019, with more than 142,000 deaths nationally (ACS,
2019). The incidence of lung cancer is slowly declining due to the decrease in tobacco
usage. In addition, the survival rates are increasing thanks to improved screening
practices and treatment modalities (ACS, 2019; de Moor et al., 2013). The 5-year relative
survival rate for lung cancer is up from 13% for 1987–1989 to 20% for 2008–2014 (ACS,
2019). If diagnosis precedes metastasis, the 5-year relative survival rate increases to 56%
(ACS, 2019).
The Institute of Medicine (2013), or IOM, reported that 14 million cancer
survivors lived in the United States in 2012. By 2022, this number will increase to 18
million (IOM, 2013). This population will encompass a growing number of lung cancer
survivors, whose survival rate is defined by the time from diagnosis until the end of life
(IOM & NRC, 2006). It is imperative for researchers to identify, examine, and gain a
better understanding of the potential and current issues that cancer survivors encounter
over the course of their disease. This is especially crucial for lung cancer survivors in
light of the particular challenges they face.
Lung cancer survivors experience significant physical symptom burden,
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psychological distresses, and social challenges alongside their disease process and
treatment options (Brown-Johnson et al., 2015; Chambers et al., 2012; Chambers, Baade
et al., 2015; Chapple, Ziebland, & McPherson, 2004; Gonzales & Jacobsen, 2012;
Gonzalez et al., 2015; Hamann et al., 2014; Houlihan & Tyson, 2012). The presence of
pain, breathlessness, loss of appetite, fatigue, insomnia, and difficulty swallowing are
common among lung cancer survivors and adversely affect their overall quality of life
(Fiteni et al., 2016; Houlihan & Tyson, 2012; Rauma, Sintonen, Räsänen, Salo, & Ilonen,
2015). These physical symptoms also affect the ability to successfully master normal dayto-day activities of living and alter social well-being, which is important for overall
health (World Health Organization, 2017). Lung cancer survivors also experience a
higher level of psychological distress such as depression and anxiety (Brown-Johnson,
Brodsky, & Cataldo, 2014; Cataldo, Jahan, & Pongquan, 2012; Chambers et al., 2012;
Chambers, Baade et al., 2015; Chapple et al., 2004; Gonzales & Jacobsen, 2012; Hamann
et al., 2014). These psychological distresses may be exacerbated by perceptions and
actions of others related to a lung cancer diagnosis.
Health-related stigma affects many aspects of life for individuals living with a
disease such as lung cancer (ALA, 2014; Cataldo et al., 2012; Chapple et al., 2004;
Hamann et al., 2014; Gonzalez & Jacobsen, 2012; Lehto, 2014). One example of a
health-related stigma is lung cancer stigma, which is negatively associated with quality of
life (QOL) and survival rates of individuals living with lung cancer (Brown-Johnson et
al., 2014; Cataldo et al., 2012; Cataldo, Slaughter, Jahan, Pongquan, & Hwang, 2011;
Chambers, Baade et al., 2015; Rauma et al., 2015; Rowland et al., 2014).
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History and Background of Lung Cancer Stigma
Stigma is an undesirable stereotype that places an individual in a group that is
devalued because of a particular attribute (Goffman, 1963). A health-related stigma is the
perception of possessing a trait that produces an unfavorable outcome (Berger, Ferrans, &
Lashley, 2001). In the case of lung cancer, the trait is the behavior of cigarette smoking,
which leads to the unfavorable outcome of a lung cancer diagnosis (Cataldo et al., 2012).
Lung cancer stigma is a complex concept intertwined with cigarette smoking and has a
widespread effect on the physical, psychological, and social well-being of lung cancer
survivors (Brown-Johnson et al., 2014; Cataldo et al., 2012; Chambers, Baade et al.,
2015; Criswell, Owen, Thornton, & Stanton, 2016; Gonzalez & Jacobsen, 2012; Hamann
et al., 2014).
Cigarette smoking and lung cancer have a well-established relationship. In 1964,
the U.S. Surgeon General’s advisory report, Smoking and Health, provided
groundbreaking information for medical professionals, public health officials, and the
general public on the link between cigarette smoking and the development of chronic
diseases (U.S. Department of Health and Human Services Public Health Office of the
Surgeon General [OSG], 2014). Subsequent Surgeon General reports further cemented
cigarette smoking as an environmental health hazard (OSG, 2014). These reports
prompted public health initiatives, education, and federal and state policies that focused
on decreasing tobacco usage and eliminated smoking from public places in the United
States (Bayer, 2008). Although these well-intentioned public health efforts were initiated
to eliminate tobacco usage, they changed societal views about both cigarette smoking and
those who smoke (Bayer, 2008). These initiatives prompted new rhetoric from tobacco

3

companies, labeling smoking as a “choice.” This message implicitly defended cigarette
manufacturers’ profits and thrust the responsibility for cigarette smoking—along with the
development of chronic debilitating diseases linked to smoking, including lung cancer—
onto individuals (ALA, 2014).
In 1988, the U.S. Surgeon General reported that nicotine and cigarette additives
harbor addictive properties. Nonetheless, stigmatization continues to occur for
individuals who currently smoke or previously smoked cigarettes. Even though cigarette
smoking also contributes to the development of other types of cancer—including bladder,
colorectal, kidney, and liver cancer—cigarette smokers are deemed responsible for their
“choice” and are most commonly blamed for the development of lung cancer (ALA,
2014; Daher, 2012; Lebel et al., 2013). The interrelated dimensions of cigarette smoking
and lung cancer result in a layered effect of stigma for lung cancer survivors and can have
a significant, far-reaching impact on the lives of lung cancer survivors (Chambers, Baade
et al., 2015; Criswell et al., 2016; Webb & McDonnell, 2018).
Lung cancer researchers, governmental agencies, and nonprofit organizations
acknowledge the presence of lung cancer stigma and its impact on lung cancer survivors
(Cataldo et al., 2012; Chapple et al., 2004; Lehto, 2014; Hamann et al., 2014; Gonzalez &
Jacobsen, 2012). The number of studies evaluating lung cancer stigma has increased
since 2011. However, few research studies measure lung cancer stigma and its
association with QOL measures (physical, psychological, and social well-being) in a
population that experiences a proportionately greater rate of lung cancer incidence and
mortality than other groups: African Americans.
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For the year of 2016, the ACS estimated more than 24,000 lung cancer diagnoses
were made among African Americans, comprising 13% of all cancer diagnosis for this
population, with more than 17,000 deaths resulting from the disease (ACS, 2016). The 5year relative survival rate for lung cancer is lower in African Americans (14%) compared
to the rate among Caucasians (18%) (ACS, 2016). A 2018 report by the Centers for
Disease Control and Prevention (CDC) ranked South Carolina 16th in lung cancer
incidence. Among those with lung cancer in the state, African American males display a
higher age-adjusted incidence and lower survival rate (88% and 13.4%, respectively) than
Caucasian males (78.8% and 15.5%), while African American women have a lower ageadjusted incidence and survival rate (39.5% and 19.1%, respectively) than Caucasian
women (56.1% and 21.6%) (CDC, 2018). This disparity among African Americans in
general, and in South Carolina in particular, is disconcerting.
There are factors to consider given this cancer disparity between African
Americans and those of other races/ethnicities in South Carolina. Evidence from research
indicates African American cancer survivors experience a higher level of depressive
symptoms, which negatively influence overall QOL (Traeger, Cannon, Pirl, & Park,
2013). Additional inquiry is warranted to gain a better understanding of stigma and to
evaluate its effect on psychological challenges as well as on overall QOL. An equal
representation of African American and Caucasian lung cancer survivors will allow
examination of lung cancer stigma, depressive symptoms, and QOL outcomes, especially
as they may differ between populations. This research will expand existing knowledge of
lung cancer stigma and may assist with tailored interventions to improve QOL and
survival rates among lung cancer survivors, particularly African Americans.
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Specific Aims and Hypotheses
The Cataldo Lung Cancer Stigma Scale (CLCSS), adapted in 2011 from Berger’s
HIV Stigma Scale, is the first validated health-related stigma instrument specifically
designed to evaluate those living with lung cancer (Cataldo et al., 2011). CLCSS
evaluates perceived stigma using four domains: stigma and shame, discrimination, social
isolation, and smoking. However, this instrument has not been evaluated for readability
and content validity among African American survivors of lung cancer. The purpose of
this dissertation study is to evaluate lung cancer stigma and its association with
depressive symptoms and QOL outcome measures among survivors of lung cancer, with
equal representation of Caucasians and African Americans living with a lung cancer
diagnosis in South Carolina. The goal of this research is to enhance existing knowledge
of stigma and its effect on individuals in South Carolina living with a lung cancer
diagnosis. The specific aims of this dissertation study are as follows:
1. Evaluate reliability and construct validity of the Cataldo Lung Cancer Stigma
Scale on a purposive sample of Caucasians and African Americans in South
Carolina with a history of lung cancer, stages Ia–IV.
2. Calculate and compare levels of stigma, depression, and QOL for each race,
gender, and smoking status.
3. Evaluate the relationship between lung cancer stigma and race, adjusting for
all other demographic variables.
4. Explore the experiences of African American lung cancer survivors relative to
stigma and the interpretation of the CLCSS.
The following hypotheses will be tested:
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1. The CLCSS will demonstrate internal consistency among this population of
lung cancer survivors, with a Cronbach’s alpha of greater than 0.7.
2. There will be a statistically significant positive association between lung
cancer stigma and depressive symptoms.
3. There will be a statistically significant negative association between lung
cancer stigma and quality of life.
4. There will be a statistically positive relationship between lung cancer stigma
and race after adjusting for other demographic variables.
Theoretical Framework
Cataldo and colleagues developed the Lung Cancer Stigma Model based on
Berger and colleagues’ 2001 HIV Stigma Model (Berger et al., 2001; Cataldo et al.,
2011). Both models led to the development of scales to measure stigma in the healthrelated population each model addressed. Lung cancer and HIV stigma share some
common threads. Both originate from the perspective that the individual is responsible
for the development of the disease due to individual choices and behaviors. Both are
therefore considered to be self-inflicted. Studies indicate that individuals with HIV and
lung cancer share tremendous symptom burden, high levels of anxiety and depression,
and social challenges such as isolation and rejection related to their diagnoses (Buseh,
Kelber, Hewitt, Stevens, & Park, 2006; Chambers et al., 2012; Levi-Minzi & Surratt,
2014). The perspective of those around them influences survivors of lung cancer. These
influences may alter different aspects of their lives over the span of the disease. For this
reason, it is important that a conceptual model address the various factors that may
influence the experiences the survivor may have.
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The Lung Cancer Stigma Model consists of three identified dimensions: (1)
precursors, (2) perceptions, and (3) responses (see Figure 1.1; Brown-Johnson et al.,
2015; Cataldo et al., 2011). These dimensions represent the perceptions, internalized
feelings, and experiences of lung cancer survivors relative to stigma. These stages usually
occur sequentially. The precursor stage involves the survivors’ awareness of societal
views toward a lung cancer diagnosis and their personal views of having the disease. This
stage encompasses survivors’ awareness of the stigma of cigarette smoking and the
knowledge that smoking may be a contributing factor in the development of lung cancer.
The perceptions stage encompasses perceived stigma of having lung cancer. At this point,
lung cancer survivors perceive the actual or potential negative appraisal from others
resulting from their diagnosis. The negative appraisal from others can lead to social
rejection and discrimination. There is potential for identity change of the survivor as
result of the negative appraisal of others. This can, in turn, result in shame and blame
related to smoking and the development of the cancer. The consequences of stigma, as
well as coping mechanisms, are addressed in the response stage. Perceived stigma can
directly or indirectly influence dimensions of QOL for survivors (Brown-Johnson et al.,
2014). This includes physical, psychological, and social well-being. Physical well-being
includes symptom burden for the lung cancer survivor. Psychological well-being
encompasses, but is not limited to, anxiety, depression, and coping (Gonzalez &
Jacobsen, 2012). Social well-being includes challenges such as withdrawal and
avoidance. Within the response stage, positive results are possible. For example, there is
a chance that the experience of stigma could lead to a therapeutic result or a change in
priorities or worldview (Hamann et al., 2014).
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Proposed Conceptual Model
This dissertation will be guided by the principal investigator’s adapted model of
the Lung Cancer Stigma Model (see Figure 1.2). This adapted model will provide the
framework for examining the association among lung cancer stigma, depression, and
QOL. As noted, the survivor of lung cancer may perceive societal attitudes relative to
smoking and a lung cancer diagnosis. The survivor may also be aware of potential or
actual behaviors exhibited by others and feelings that may occur because of this
perception. This may lead to feelings that negatively affect their identity-stigma and
shame. The perceptions and feelings of the survivor may also be associated with
depression and lower QOL, thereby affecting the chance of survival.
Research Design, Methods, and Data Analysis
Research Design
To address the purpose and specific aims, quantitative and qualitative methods
were used. Correlational analysis was used to analyze and quantify relationships among
lung cancer stigma, depression, and QOL measures. To examine the relationship between
lung cancer stigma and race, a generalized linear model was used. All demographic
characteristics were assessed for statistically significant relationships with lung cancer
stigma. Interviews were conducted with African American participants to ascertain their
experiences regarding lung cancer stigma and their interpretation of the CLCSS.
Sample
The institutional review boards (IRBs) of the University of South Carolina (USC)
and Palmetto Health (PH) in Columbia, South Carolina, approved this research. The PH
cancer registry of approximately 500 potential participants was used for recruitment.
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Equal percentages of Caucasian and African American survivors were initially targeted
for recruitment. A power analysis was conducted to determine a sufficient sample for an
alpha cutpoint of .05, a power of .80, and a large effect size of .35 (Grove, Burns, &
Gray, 2013). This analysis indicated a desired sample size of 52, with 26 Caucasians and
26 African Americans. With Pearson correlation analysis, the total sample size of 13 is
required to determine whether a correlation coefficient differs from zero with an alpha of
0.05 and beta of 0.2 (Polit & Beck, 2008). To be eligible for enrollment in this study, an
individual must have (1) been 21 years of age or older; (2) had a personal history of lung
cancer; (3) been able to speak and read English; and (4) resided in South Carolina.
Recruitment
The primary recruitment method was an IRB-approved recruitment letter and
flyer, indicating the purpose and procedure of the study; the flyer was mailed to potential
participants who were identified by a cancer data system from PH hospitals located in
Columbia, South Carolina. Palmetto Health Cancer Centers are American College of
Surgeons–accredited cancer programs where patient tracking is maintained by a cancer
registry. Over a 4-month time period, a letter and flyer were sent to 500 survivors with a
lung cancer diagnosis. A follow-up telephone call was made within 1–2 weeks. Potential
participants had the option of having the surveys mailed to them, administered verbally
via telephone, or administered in person by the principal investigator (PI) at a convenient
location. The secondary recruitment method was face-to-face meeting with survivors in
attendance at a Breathe Easier Club meeting held monthly over a 2-month period. The
Breathe Easier Club is a support group for lung cancer survivors in Greater Columbia,
South Carolina. The third and final recruitment strategy was placement of recruitment
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flyers at strategic areas of South Carolina Oncology Associates, an ambulatory cancer
care treatment center. Face-to-face introductions between lung cancer survivors and the
PI were made during the survivors’ appointment visits, with the assistance of oncology
nurses. Any participant who completed the survey and/or an interview was given an
appreciation gift (a gift card to a local retail store).
Measures
The first instrument used was the CLCSS. This 31-item, 4-point Likert scale
evaluates stigma. The original psychometric testing was conducted in 2011 (Cataldo et
al., 2011). Construct validity was determined by exploratory factor analysis, which
identified the four domains: stigma and shame, social isolation, discrimination, and
smoking. Construct validity was supported by known relationships among related
constructs of self-esteem, depression, social support, and social conflict (Cataldo et al.
2011). The developer of the CLCSS has given permission for our use of this instrument.
(See Appendix A for a sample of the scale and permission for use of the scale).
The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item
self-report scale (Radloff, 1977). This instrument assesses eight domains of depression:
depressed mood, feelings of guilt, feelings of worthlessness, feelings of helplessness,
feelings of hopelessness, psychomotor retardation, loss of appetite, and sleep disturbance.
This scale has been shown to be reliable with clinical and general populations of males
and females, and both Caucasians and African Americans. It has a high internal
consistency ranging from 0.85 to 0.90 (Radloff, 1977). This instrument is in the public
domain. (See Appendix B.)
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The European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire Core 30 (EORTC QLQ-C30) measures QOL in individuals with a cancer
diagnosis (Aaronson et al., 1993). There are supplements for specific cancer types that
accompany the original instrument. For our study, a lung cancer supplement of 13
questions was added to the original survey. This scale was tested on lung cancer patients
(n = 110) and yielded an acceptable internal consistency of 0.70 (Nicklasson & Bergman,
2007). Criterion validity was supported by correlation with clinical parameters that
addressed all domains of the instrument (Nicklasson & Bergman, 2007). This instrument
is in the public domain. (See Appendix C.)
The primary investigator developed a demographic form to collect information
about each participant that included gender, age, race, annual household income, year of
lung cancer diagnosis/staging of cancer, self-report of health status, smoking status,
educational attainment level, and employment data. (See Appendix D.)
Analysis
The study variables—stigma, depression, and QOL—were summarized using
frequencies (for categorical variables) or means with standard deviations (for continuous
variables) (DePoy & Gitlin, 2011). Demographic characteristics, lung cancer stigma,
depression, and QOL were tested for bivariate associations using t-tests for continuous
variables (Grove et al., 2013). Relationships between the demographic characteristics and
outcome variables were tested using the independent t-test and analysis of variance
(ANOVA). Pearson’s correlations were used to assess associations between continuous
demographic variables and the main outcome variables. Statistical analysis was computed
via SPSS® version 25. Cronbach’s alpha was used to determine internal consistency. A
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value of 0.7 is considered acceptable (Grove et al., 2013). The CLCSS had established
construct validity from the original psychometric testing. For this study, it was imperative
to determine if the instrument maintains construct validity. Depression and QOL were the
constructs chosen to assess bivariate correlation with stigma. The desired goal was to
obtain correlations with large strength among constructs, establishing strong associations
and validating the direction of the relationship between the variables as well as the degree
of variance (Grove et al., 2013).
To determine the relationship between lung cancer stigma and race, a generalized
linear model was used. Independent variables/demographics were evaluated for
statistically significant relationships with stigma and race by utilizing a bivariate analysis
to determine significance. The final model was tested by utilizing any demographic
variable that met the requirement of a having a statistically significant relationship with
race and lung cancer stigma.
The CLCSS has not been evaluated specifically among African American lung
cancer survivors for cultural considerations and construct validity using an adequate
sample size. In order to address this deficit, the PI conducted individual interviews, using
semi-structured guide with 10 African American participants who had previously
completed the study surveys. The goal of these interviews was to understand how the
participants viewed each statement and to ascertain if the CLCSS questions were
appropriate concerning language and their ability to capture the essence of stigma.
Overview of Manuscripts and Target Journals
Lung cancer stigma affects survivors, family members, and health professionals.
Specifically, stigma affects the diagnosis of lung cancer, treatment modalities, survival

13

rates, and QOL. Articles generated by this study will be published in journals whose
readership consists of health-care professionals treating and caring for an individual with
or recovering from this disease.
The first manuscript is a scoping literature review of lung cancer stigma. The
review synthesized quantitative and qualitative studies to help conceptualize lung cancer
stigma, identify instruments used to evaluate and quantify this stigma, and determine
gaps in the literature or areas needing further investigation. This manuscript has been
accepted for publication in Oncology Nursing Forum, with an anticipated publication of
July 2019.
The next manuscript discusses our study’s mixed methods approach involving
results from African American participants. The manuscript includes the qualitative
component of the data investigating African Americans’ perspectives of lung cancer
stigma and the interpretation of the CLCSS. The quantitative data analysis will correlate
stigma, depression, and global health in this sample. This manuscript will be submitted to
the Journal of Psychosocial Oncology in May 2019.
The third manuscript will consist of results of the entire sample evaluating the
correlations of stigma, depression, and QOL, comparing these relationships for African
American and Caucasian lung cancer survivors. That evaluation will include regression
analysis to assess the relationship between stigma and race, adjusting for other
demographic characteristics. That third manuscript will be submitted to the European
Journal of Oncology Nursing in May 2019.
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Precursors
Perceptions of societal attitudes toward smokers and people with lung cancer
Knowledge of self as having lung cancer

Perceived Stigma of Having Lung Cancer (aware of actual or potential)
Social disqualification (social isolation subscale)
Limited opportunities (discrimination subscale)
Negative change in identity (stigma and shame, and smoking subscales)

Possible Responses
Physical reactions
Physical symptom burden
Emotional reactions
Change in self-concept
Psychosocial symptom burden
Use of techniques to avoid or minimize stigma (e.g., information control,
avoidance and withdrawal, tension reduction)
Redefined worldview or priorities

Figure 1.1 Lung Cancer Stigma Model (Cataldo, Slaughter, Jahan, Pongquan, & Hwang,
2011).
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Precursors
•
•

Perceptions of societal attitudes toward smoking and lung cancer
o Blame
o Shame
Self-knowledge of having a lung cancer diagnosis

Internalized Lung Cancer Stigma

Perceived Lung Cancer Stigma
(potential or actual)

Negative change in identity—stigma
and shame/smoking

Social disqualification—Social
isolation

Self-blame
Regret
Guilt

Limited opportunities—Discrimination

Depression

Responses
Quality of Life
Functionality
Role
Emotional
Health Status

Physical
Cognitive
Social
Physical Symptoms

Figure 1.2 Proposed Lung Cancer Stigma Model.
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CHAPTER 2:
EXPLORING STIGMA AMONG LUNG CANCER SURVIVORS:
A SCOPING LITERATURE REVIEW1

1

Webb, L.A., McDonnell, K. K., Adams, S. A., Davis, R. E., & Felder, T. M. Accepted by Oncology

Nursing Forum. Reprinted here with permission of publisher, 2/14/2019. Note that ONF holds rights as the
original publisher of the data in this chapter. See Appendix E.
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Abstract
Problem Identification:
Lung cancer survivors face many challenges that affect their quality of life and survival.
A growing concern is the layered effect of stigma related to both cigarette smoking and
the perceived life-threatening diagnosis of lung cancer. This experience may affect lung
cancer survivors’ physical, psychological, and social well-being, thus negatively
influencing their quality of life.
Literature Search:
CINAHL, PubMed, PsycINFO, and Web of Science were searched from the period of
January 2000 through August 2017, using combinations of four keywords: lung cancer,
lung neoplasm, stigma, and smoking.
Data Evaluation:
Extracted data include research aim(s), design, method, analytical approach, sample size,
gender, ethnicity/race, setting, stigma measure, smoking status, and major results.
Synthesis:
Of 163 studies initially identified, 30 studies (7 qualitative, 10 quantitative, 1 mixed
method, 1 systematic review, and 1 meta-analysis) were included. An evidence table
presents studies alphabetically in chronologic order according to publication year.
Quantitative studies were analyzed by statistically relevant results, whereas thematic
analysis was used to evaluate qualitative studies. Instruments assessing stigma in the
review are listed alphabetically.
Conclusions:
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These studies affirm that lung cancer stigma is associated with feelings of self-blame,
anger, regret, and guilt, and with perceptions of shame, discrimination, and blame. These
feelings and perceptions may negatively affect the overall well-being of lung cancer
survivors. This review offers an understanding of lung cancer stigma and provides
substantial data that may lead both to the development of intervention(s) that aim to
reduce the consequences of stigma and to improved overall quality of life for lung cancer
survivors.
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Background
Lung cancer is the second-leading cause of cancer among adults, accounting for
27% of all cancer deaths in the United States (American Cancer Society [ACS], 2018;
American Lung Association [ALA], 2018). Due to advances in screening practices, early
detection, and improved treatments, lung cancer survival rates continue to improve (ACS,
2018; de Moor et al., 2013). In 2018, the 1-year and 5-year survival rates for lung cancer
were 50% and 18%, respectively, up from 37% and 15% in 2013 (ACS, 2018; ALA,
2018).
The Institute of Medicine (2013) reported that 14 million cancer survivors lived in
the United States in 2012, a number projected to rise to 18 million by 2022. The
increasing cancer survival rates, including the rising lung cancer survival rates—defined
as the average time between diagnosis and end of life—warrant examination to
understand the challenges these survivors face, especially stigma.
Stigma is “an undesirable stereotype leading people to reduce the bearer from a
whole and usual person to a tainted, discounted one” (Goffman, 1963, p. 3). Healthrelated stigma is the perception of possessing a trait that produces an unfavorable health
outcome. For lung cancer, the health-related stigma is a perception that individuals
diagnosed with lung cancer must be tobacco users, because tobacco use is the leading
cause of lung cancer (Cataldo, Slaughter, Jahan, Pongquan, & Hwang, 2011). Today,
cigarette smoking is viewed as a poor life choice, and individuals who make this choice
are perceived as being responsible for their lung cancer diagnosis (Cataldo et al., 2011;
Lehto, 2014). This perception grew out of the U.S. Surgeon General’s 1964 report
Smoking and Health, which heightened public awareness of the effects of tobacco use
and its link to chronic illnesses. Subsequent Surgeon Generals have validated that
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groundbreaking finding and revealed more concerns regarding tobacco use that affect
non-smokers (U.S. Department of Health and Human Services Public Health Office of
the Surgeon General, 2014). Now-pervasive antismoking initiatives have denormalized
smoking, leading to smokers being blamed for diseases with which their behavior is
linked (Bayer, 2008; Gielen & Green, 2015; Peretti-Watel, Legleye, Guignard, & Beck,
2014).
Lung cancer survivors experience higher levels of psychological distress
compared to other cancer survivors (Brown-Johnson et al., 2015; Chambers, Baade et al.,
2012; Chambers, Morris et al., 2015; Chapple, Ziebland, & McPherson, 2004; Gonzalez
& Jacobsen, 2012; Hamann et al., 2014). Stigma is thought to lead to further
psychological distress and social isolation, and to negative effects on physical and
functional well-being (Brown-Johnson et al., 2015; Cataldo et al., 2011; Chambers et al.,
2012; Chambers, Baade et al., 2015; Gonzalez & Jacobsen, 2012; Hamann et al., 2014).
Although there is acknowledgement of the negative ramifications of lung cancer
stigma, there are scant studies addressing possible interventions for oncology health
professionals to assist with alleviating the significant effect stigma has on lung cancer
survivors. One of the first studies that contributed to the conceptualization of lung cancer
stigma dates back 14 years (Chapple et al., 2004). To date, existing research has
evaluated lung cancer stigma and its impact on physical, social, and psychological
challenges experienced by survivors. Examination of existing literature will not only
assist with enhancing the conceptualization of lung cancer stigma, but also identify gaps
and provide suggestions for oncology practice and future research. The authors chose a
scoping review to provide this direction. This review captures emerging knowledge,
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identifies areas where scientific advancement is needed, and seeks to contribute to the
future development of interventions that will mitigate stigma-induced distresses and
improve survivors’ quality of life (QOL).
Methods
Using the process delineated by Arksey and O’Malley (2005), a scoping review
was conducted of the stigma experience among lung cancer survivors. The five-step
process involved (1) identifying the research question; (2) identifying relevant studies;
(3) selecting the studies; (4) charting the data; and (5) summarizing the data and reporting
results. Following this process, pertinent research questions were identified and included:
(1) How is lung cancer stigma measured?; (2) How can we fully describe the stigma lung
cancer survivors face?; and (3) How does lung cancer stigma affect survivors’ overall
QOL? Existing research was delineated by the measures of lung cancer stigma, the scope
and depth of stigma among adult lung cancer survivors, and the impact stigma has on
QOL. Existing research was categorized and summarized. Clarification of the conceptual
definition and identification of research gaps were reported, and suggestions of future
paths for research were recommended (Peters et al., 2015).
Identification of Relevant Research Studies
CINAHL, PubMed, PsycINFO, and Web of Science were used to identify research
studies published between January 2000 and August 2017. Searches included four
keywords in the following combinations:
•

Lung neoplasm AND stigma

•

Lung cancer AND stigma AND smoking

•

Lung neoplasm AND stigma AND smoking
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•

Lung cancer AND stigma OR smoking

•

Lung neoplasm AND stigma OR smoking
Keywords could appear in the title, abstract, and/or body of the article. For an

article to be included, it had to be published in English in a peer-reviewed journal. The
inclusion criteria also required that sample participants be age 18 or older and survivors
of small-cell or non-small-cell lung cancer. Studies that did not consider stigma
associated with lung cancer as one of its aims were excluded from the review. Studies
included must have examined stigma or an outcome variable associated with lung cancer
stigma, such as—but not limited to—smoking status, depressive symptoms, and QOL.
Previous studies using either qualitative and quantitative research methodologies were
included.
A search across all four databases yielded 163 articles (see Figure 2.1). Duplicate
articles (n = 114) and non-research articles, commentary articles, and theoretical reviews
(n = 48) were excluded. After making these exclusions, 30 relevant publications remained
and were included in our review (see Table 2.1). Existing research was delineated,
categorized, and summarized by the study methods, measures of lung cancer stigma, the
scope and depth of stigma among adult lung cancer survivors, and the impact stigma has
on QOL.
Data Extraction, Analysis, and Synthesis
Evaluated data included research aim(s), design, method, analytical approach,
sample size, gender, ethnicity/race, setting, stigma measure, smoking status, and major
results. Studies aimed to define internal, external, and perceived stigma and to understand
the health consequences and QOL impact stigma has on lung cancer survivors. Evidence
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tables were developed to organize quantitative and qualitative data chronologically and in
alphabetic order relative to date of publication. Instruments measuring stigma were
organized in alphabetical order.
Results
Overview of Studies Reviewed
The four earliest studies were published between 2004 and 2009; the remaining
26 were published since 2011. A majority of studies (n = 17) were conducted in the
United States. Others took place in Australia (n = 3), the United Kingdom (n = 3),
Canada (n = 2), China (n = 2), and Korea (n = 1). The remaining two studies were
literature reviews, one a systematic review and the other a meta-analysis. (See Table 2.1.)
The U.S.-based studies evaluated lung cancer stigma that represented three different
regions: Northwest, Midwest, and Southeast. Study designs included analysis of
covariates, correlational analysis, factor analysis, multiple linear regression, and repeated
measures with interventions. Study participants were generally homogeneous in terms of
ethnicity (Caucasian) and in the age range of 60–65 years. Participants included even
numbers of males and females.
The studies’ aims included understanding the impact on QOL related to stigma
experienced by lung cancer survivors, specifically depression, guilt, shame, caregiver
support, and patient-provider communication from the survivors’ perspectives.
Interestingly, not all studies reported smoking status of the participants. Studies that did
report smoking status reported a higher incidence of stigma among current and former
smokers. Seven studies used an exploratory approach through a qualitative design. This
allowed researchers to capture participants’ perspectives on stigma, societal attitudes
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toward smoking and lung cancer, challenges related to stigma, and positive and negative
results from the experience of stigma. In the articles included, investigators used survey
instruments to measure lung cancer stigma, anger, anxiety, casual attribution, depression,
QOL, self-blame, timing of medical help, diagnosis concealment, and/or provider-patient
communication. One systematic review, published in 2012, assessed lung cancer stigma
and its association with nihilism, health-related outcomes, and public health programs,
and included studies with medical professionals as participants along with studies
focused on support programs. Of the18 articles in the systematic review, this scoping
review included three. In 2014, a meta-synthesis explored the experience of stigma
among lung cancer survivors. Because of the meta-synthesis review’s broad aims, seven
qualitative research studies were included.
Stigma Instruments
To evaluate lung cancer stigma among survivors, researchers measured stigma
and related constructs with six instruments across the 30 studies (see Tables 2.1 and 2.2).
The Cataldo Lung Cancer Stigma Scale (CLCSS) was used in nine studies. This 31-item
instrument was adapted from Berger’s HIV Stigma Scale (Berger, Ferrans, & Lashley,
2001; Calatdo et al., 2011). The four factors that emerged from this instrument (stigma
and shame, social isolation, discrimination, and smoking) represent perception, blame
and shame from others, the feeling of social strain and judgment, and the responsibility of
acquiring the disease. Carter-Harris and Hall (2014) conducted a psychometric analysis
and reduced the item number of the CLCSS to 21.
LoConte, Else-Quest, Eickhoff, Hyde, and Schiller (2008) developed a six-item
scale—derived from qualitative data obtained from previous lung cancer survivors’ focus
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group discussions—called the Perceived-Cancer Related Stigma Scale. This instrument
assessed self-blame, guilt, shame, and embarrassment among lung, breast, and prostate
cancer survivors. Gonzalez and Jacobsen (2012) and Gonzalez and colleagues (2015)
used the Social Impact Scale to measure the perception of stigma in relation to social
rejection, financial insecurity, internalized shame, and social isolation. This scale
assessed stigma in cancer populations and individuals diagnosed with HIV/AIDS. Shen
and colleagues (2015) adapted the Head and Neck Cancer Shame and Stigma Scale (SSS)
for lung cancer survivors. The SSS assessed perceived and internalize stigma, and the
feelings of guilt and regret related to cigarette smoking.
The Lung Cancer Stigma Inventory (LCSI) was developed by Hamann, Shen,
Thomas, Lee, and Ostroff (2017). This 25-item instrument was derived from the
conceptual model of lung cancer stigma developed earlier by Hamann and colleagues
(2014). Three subscales emerged: perceived stigma, internalized stigma, and constrained
disclosure. The LCSI was psychometrically evaluated and had adequate internal
consistency and convergent validity with related constructs. Lebel, Castonguay et al.
(2013) and Lebel, Feldstain et al. (2013) both used the Explanatory Model Interview
Catalogue. This semi-structured interview was adapted into a 13-item questionnaire that
explored stigma and illness disclosure and social rejection related to stigma. To date there
are two instruments (the CLCSS and the LCSI) specifically prepared to evaluate lung
cancer stigma that have been psychometrically tested and proven to have adequate
reliability and validity.
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Definitions of Lung Cancer Stigma
Goffman’s (1963) work was the basis for a majority of studies (n = 13) in
defining health-related stigma conceptually. His work laid the foundation for the initial
conceptualization of stigma. He defined stigma as “an attribute that is deeply
discrediting,” where the attribute in question is different from the normal status quo
(Goffman, 1963, p. 3). A cancer diagnosis is often stigmatized because of a general
misunderstanding or fear of cancer (Daher, 2012). Stigma can increase when a particular
lifestyle or behavior is linked to the cancer (Cataldo et al., 2011; Lehto, 2014), as in the
case of lung cancer and cigarette smoking (ALA, 2014; Dela Cruz, Tanoue, & Matthay,
2011). Although Goffman provided the foundation, researchers since then have given
different but meaningful definitions and descriptions of lung cancer stigma. This is true
even though associated constructs are in alignment with all descriptions and definitions of
stigma and its overall effects on lung cancer survivors’ QOL.
Types of Stigma: Internal, External, and Perceived
Chapple et al. (2004); Hamann et al. (2014); Lebel, Castonguay et al. (2013); and
Shen, Hamann, Thomas, and Ostroff (2016) described stigma as having both internal
(felt) and external (enacted) components. Felt stigma is internal to the survivor; examples
include feelings of shame and guilt (Chapple et al., 2004; Lebel, Castonguay et al., 2013).
Chapple et al. (2004); Hamann et al. (2014); and Tod, Craven, & Allmark’s (2008)
qualitative studies reported participants feeling shame and guilt, which diminished their
tendencies to seek health care, social interaction, and support. Internalized feelings may
manifest as negative outcomes, such as social isolation and depression. Enacted stigma is
external to the survivor, but is directed toward him or her from others, producing an
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action (reaction or behavior) such as discrimination, blame, or social rejection (among
other negative behaviors) (Chapple et al., 2004; Gonzalez & Jacobson, 2012). Stigma has
been characterized as a perception that is felt by both the survivor and others (BrownJohnson et al., 2014; Cataldo, Jahan, & Pongquan, 2012; Cataldo et al., 2011; Criswell,
Owen, Thornton, & Stanton, 2016; Gonzalez et al., 2015). Perceived stigma is the
negative feeling survivors believe others have toward them and their cancer diagnosis
(Brown & Cataldo, 2013; Cataldo et al., 2011; Chambers Baade et al., 2015; Lehto,
2014).
Our study concluded that lung cancer stigma is a threefold concept that involves
survivors’ perceptions, survivors’ internalized feelings, and the feelings and actions of
others toward survivors. There is often interplay among felt, enacted, and perceived
stigma, amplifying or reinforcing the other stigmas. For example, lung cancer survivors
are aware that others may believe that their cancer is self-inflicted via tobacco use, and
that they may therefore be held responsible for their diagnosis. The anticipated blame,
discrimination, and social rejection may lead to a sense of internal shame (Cataldo et al.,
2011; Lehto, 2014).
Health Consequences of Stigma Among Lung Cancer Survivors
Of the studies that reported smoking status (n = 23), lung cancer survivors felt
some sense of responsibility for their disease regardless of their smoking status (Brown &
Cataldo, 2013; Cataldo et al., 2012; Cataldo et al., 2011; Else-Quest, LoConte, Schiller,
& Hyde, 2009; Gonzalez et al., 2015; Shen et al., 2015). Current smokers experienced a
higher level of guilt, shame, anxiety, and depression in comparison to former and never
smokers (Cataldo et al., 2012; Else-Quest et al., 2009; LoConte et al., 2008). Former and
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current smokers also experienced a higher level of depression and anxiety in comparison
to individuals who were never smokers diagnosed with breast, colon, lung, stomach,
cervix, head, or neck cancer (Lebel, Castonguay et al., 2013; Lebel, Feldstain et al., 2013;
So, Chae, & Kim, 2017). Further validation was reported by Cataldo et al. (2011),
Cataldo et al. (2012), and Gonzalez and Jacobsen (2012), where there was a significantly
statistical strong positive association between stigma and depression with their study of
lung cancer survivors. Brown-Johnson and colleagues (2014) found significant statistical
associations among lung cancer stigma, depression, and anxiety. Chambers, Morris et al.
(2015) introduced a cognitive behavioral intervention focused on lung cancer stigma in
their pilot repeated measure study. They reported higher levels of depression, anxiety,
and stigma pre-intervention, all three of which significantly decreased post-intervention.
Stigma affects psychological challenges and also complicates patient-provider
communication (Brown & Cataldo, 2013; Brown-Johnson et al., 2014; Brown-Johnson et
al., 2015; Cataldo et al., 2011; Chambers, Baade et al., 2015; Gonzalez & Jacobsen,
2012; Hamann et al., 2014; Lehto, 2014; Shen et al., 2015; Yang, Liu, Yang, Ji, & Li,
2014). Brown and Cataldo (2013) explored the experiences of women with lung cancer
and found that lung cancer stigma negatively affected the patient-provider relationship.
Other studies reported strong associations between the presence of stigma and adverse
outcomes of depression, anxiety, self-esteem, QOL, and patient-provider communication
(Brown-Johnson et al., 2014; Cataldo et al., 2012; Chambers, Baade et al., 2015;
Gonzalez & Jacobsen, 2012; Gonzalez et al., 2015; Lehto, 2014; Yang et al., 2014).
Researchers also found that perceived and internalized stigma altered patients’
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communication with their friends, family members, and health-care providers (Brown &
Cataldo, 2013; Chapple et al., 2004; Hamann et al., 2014; Lehto, 2014).
Tod and colleagues (2008) and Scott, Crane, Lafontaine, Seale, and Currow
(2015), in their qualitative studies, reported that blame, fear, and stigma all delayed
patients’ seeking of medical assistance. Carter-Harris et al. (2014) reported from their
linear regression that lung cancer stigma was predictive of increasing the time it takes for
patients to seek care for lung cancer symptoms (X2 = 4.75, F = 12.44, p < 0.01), which
prolonged lung cancer diagnosis. Studies reported that many lung cancer survivors are
afraid of others’ reactions to their diagnosis (LoConte et al., 2008; Tod et al., 2008).
Reactions of others may include discrimination by family, friends, and health-care
providers, which led some to conceal their diagnosis (Cataldo et al., 2011; Hamann et al.,
2014; Shen et al., 2015). Gonzalez et al. (2015) found that internalized shame was a
factor for those who did not disclose their diagnosis in comparison to those who did
disclose it (n = 30/117, d = 0.63, t = -3.05, p < 0.01). Internalized shame and
nondisclosure are two factors that validate the intertwining of the constructs related to
lung cancer stigma. In addition, survivors reported experiencing feelings of isolation
from friends and family as well as feelings of loneliness (Cataldo et al., 2011, Hamann et
al., 2014). Gonzalez and Jacobsen (2012) evaluated depressive symptomology, including
social support and its relationship with stigma. They reported an inverse relationship
between social support and stigma experienced by (n=95) participants in their research
study. Internalized shame and nondisclosure are intertwined constructs related to lung
cancer stigma. Increases in depressive symptoms and anxiety have also been reported
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(Cataldo et al., 2011; Cataldo et al., 2012; Gonzalez & Jacobsen, 2012; LoConte et al.
2008).
Discussion
This scoping literature review presents the results of 30 peer-reviewed research
studies that investigated stigma and lung cancer. The studies concentrated on the
perspective of survivors and on the physical, psychological, and social influence of
stigma. The findings present varied definitions of lung cancer stigma in terms of how this
health-related stigma is experienced among survivors. Chapple and colleagues (2004)
presented a foundational conceptualization that encompassed stigma of others and
internal and perceived feelings of the lung cancer survivor. It is important to note that
lung cancer stigma is a combination of awareness of social identity and survivors’
personal identity, which in turn leads to the awareness of potential negative actions of
others. This combination may result in negative consequences for the survivors. Hamann
and colleagues (2014) captured this in their conceptual model, which led to an instrument
to measure the constructs of perceived/felt stigma and internalized/self-stigma. Hamann
and colleagues’ model with the incorporation of adaptive and maladaptive consequences
contributed to their conceptualization of lung cancer stigma.
Lung cancer stigma stems from the link between cigarettes and the disease.
LoConte and colleagues (2008) found that current or former smokers with lung cancer
experienced a higher level of guilt, shame, and perceived stigma in comparison to women
with breast cancer and men with prostate cancer. However, even never smokers
experience lung cancer stigma. In fact, Cataldo et al. (2012) found a small difference in
depression from perceived stigma and QOL among ever and never smokers. This
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indicates that individuals with lung cancer experience altered QOL outcomes and
depression regardless of their history with tobacco usage. This validates the need to
consider that any lung cancer survivor may be affected by the negative influences of
stigma.
Self-blame and guilt may affect the decision and timeliness of seeking medical
care (Carter-Harris et al., 2014). Although lung cancer survivors cannot control others’
perceptions or behaviors, perceived stigma nevertheless negatively affected their selfevaluation, leading to an internalization of the stigma. Gonzalez and colleagues (2015)
and Webb and McDonnell (2018) found that some lung cancer survivors concealed their
diagnosis from family, friends, and acquaintances. Concealment of a chronic illness
linked with stigma fosters a lack of support and social isolation. This may lead to further
devaluation of the self and increased psychological challenges that may already exist
among these survivors (Quinn, Weisz, & Lawner, 2017). Good health-care provider
communication had a direct impact on the level of internalized and perceived stigma.
Communication between providers and survivors is vital for the proper management of
lung cancer, and when this communication is positive in nature, it helps identify and
support the needs of lung cancer survivors. The quality and quantity of positive and
beneficial communication between a health-care provider and a survivor is associated
with decreased lung cancer stigma (Shen et al., 2016). When survivors sense
preconceived blame, responsibility, or fatalism from others, altered communication may
result. This may lead to their delay in seeking much-needed medical assistance and
concealment of symptoms that need assessment and management.
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Although this review summarizes and synthesizes substantial evidence regarding
lung cancer stigma, knowledge gaps remain. Certain subpopulations of lung cancer
survivors are underrepresented. African Americans, Pacific Islanders, and Native
Americans have higher incident and mortality rates among all populations diagnosed with
lung cancer (ACS, 2018). But only five studies had samples with adequate African
American representation (Carter-Harris et al., 2014; Criswell et al., 2016; Gonzalez et al.,
2015; Hamann et al., 2014; Shen et al., 2016). No study had adequate representation of
Pacific Islanders and Native Americans. Never smokers, who constitute 20% of
individuals diagnosed with lung cancer (ACS, 2018), were not adequately represented in
half of the studies. Further research is needed involving vulnerable populations, given the
increased risk of negative outcomes for those living with lung cancer.
This scoping literature review focused on stigma from the viewpoint of lung
cancer survivors; however, exploration of the perceptions of family members, friends,
caregivers, and health professionals is needed. A better understanding of how stigma
impacts family members, friends and caregivers may assist with developing strategies to
support and help survivors moderate stigma, which would improve survivors’ QOL.
Another area that warrants investigation is the influence of anti-smoking campaigns, both
on survivors’ internalization of lung cancer stigma and on the perceptions of family,
friends, and health-care providers.
Lung cancer stigma affects a growing population of cancer survivors. Advancing
knowledge of stigma can improve the care and QOL of this population. Developing
effective education programs, awareness campaigns, and interventions can assist lung
cancer survivors with the negative consequences of stigma.
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Limitations of the Review
To our knowledge, this is the first scoping review to synthesize evidence from
quantitative and qualitative studies relative to lung cancer survivors and stigma. For this
reason, a scoping review was conducted rather than a systematic review or a metasynthesis. This review evaluated research on lung cancer stigma, determined the extent
and type of research conducted to date, and identified gaps in this research area (Arksey
& O’Malley, 2005). Despite our best efforts to uncover all relevant literature, we cannot
disregard the possibility that some studies may not have been identified. Lastly, we did
not limit this review to a specific methodology. The diversity of methods may have
interfered with our ability to make accurate inferences related to lung cancer stigma.
Implications for Oncology Nursing
Oncology nurses play a significant role in the lives of survivors with lung cancer
and their family members and friends. To provide patient-centered care, it is essential for
oncology nurses to understand the harmful impact of stigma. Developing strategies to
promote meaningful communication with providers is essential for survivors and their
family members, friends, and caregivers. In clinical settings, oncology nurses can
advocate for improved communication with survivors, as well as an evaluation of stigma
along with the survivors’ physical, psychological, social challenges, and QOL, to assist
with planning individualized care. Advocating for the development and implementation
of interventions that target outcomes related to decreasing physical and psychological
burdens as well as social isolation is warranted. Although instruments have been
developed for the evaluation of lung cancer stigma, more research is needed to develop
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practical strategies to measure these constructs and develop interventions to minimize
negative effects.
Suggested Paths Forward
Future investigations examining lung cancer stigma are imperative to improve
patient-centered health care and QOL for lung cancer survivors. Research should focus
on capturing specific experiences of stigma among subpopulations and amass the
formative data that supports the development of tailored interventions for the most
vulnerable subpopulations of lung cancer survivors. Such data will assist with decreasing
the experience and consequences of stigma for all lung cancer survivors.
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Table 2.1 Lung Cancer Stigma Study Review

Study

Design/
Aim(s)

Participants
(Setting)

Method

Results/Findings

QUALITATIVE STUDIES
▪ 45 participants

▪ Stigma was felt and
enacted within this
▪ Gender not
sample; these
reported
feelings may deter
participants from
▪ 98% White
seeking support and
2% Indian
assistance (including
financial)
▪ Smoking status ▪ Participants
not reported
expressed anger that
they were blamed for
(United Kingdom) acquiring the disease

Chapple,
Ziebland,
and
McPherson
(2004)

Qualitative/
Explore
perception of
stigma among
lung cancer
patients

One-to-one
interviews
focused on the
perception of the
cause of illness
and how others
reacted to the
diagnosis

Tod,
Craven,
and
Allmark
(2008)

Qualitative/
Evaluate
delayed
reporting of
lung cancer
symptoms

Individual
▪ 20 participants
interviews
utilizing
▪ 60% male
framework
40% female
analysis for
interpreting data ▪ 40% current
45% former
15% never
smokers
▪ Race/ethnicity
not reported

▪ Participants stated
that symptoms were
varied and
nonspecific
▪ Generally lacked
knowledge regarding
symptoms, diagnosis,
and treatment
▪ Shame and guilt,
fear, and stoicism
were experienced
among participants

(United Kingdom)
Brown and Qualitative/
Cataldo
Explore the
(2013)
experience of
female longterm lung
cancer
survivors in
the context of
LCS and
examine how
participants
discursively
adhere to or

Exploratory
one-to-one and
group interviews
focused on
diagnosis,
experience with
health-care
providers,
experience of
attitudes toward
lung cancer,
changes in
social network,
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▪ 8 participants
▪ 100% female
▪ 62.5% ever,*
37.5% never
smokers
(USA/Northwest)

▪ Experienced stigma
in interactions with
health providers
▪ Expressed
displeasure (negative
connotation) in how
they’re identified
(smoker, lung cancer
patient)
▪ Conflict between
rejecting and
assuming stigma
relative to diagnosis

Study

Design/
Aim(s)

Participants
(Setting)

Method

Results/Findings

reject
stigmatizing
beliefs

and experience
with stigma

▪ Expressed that LCS
interferes with an
ideal patient-provider
experience/
relationship

Hamann et Qualitative/
al. (2014)
Explore a
conceptual
model for
LCS

Individual
interviews and
focus group
discussions to
explore and
describe the
perception of
lung cancer
survivors’

▪ 42/65 individuals ▪ Perceived stigma
for interviews:
was pervasive
throughout the entire
▪ 48% male
sample, manifesting
52% female
as devaluation and
negative appraisal
▪ 64% Caucasian ▪ Internalized stigma
29% African
was affected by
American
smoking history;
2% American
long-term quitters
Indian/Alaska
and never smokers
Native
experienced less
5% Asian or
internalized stigma
Pacific Islander
▪ Stigma-related
consequences were
▪ 24% current
seen as adaptive and
50% former
maladaptive;
26% never
recognized the need
smoker
for intervention to
promote adaptive
▪ 23/65 individuals consequences
in focus group
discussions:
▪ 52% male
48% female
▪ 70% Caucasian
22% African
American
9% Asian or
Pacific Islander
▪ 17% current
48% former
35% never
smokers
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Study

Design/
Aim(s)

Participants
(Setting)

Method

Results/Findings

▪ 17% current
48% former
35% never
smokers
(USA/Southwest)
Focus group
interviews
focused on
discussing
patient
perceptions of
lung cancer
challenges and
adaptation
issues

▪ 11 participants

Lehto
(2014)

Qualitative/
Aim 1:
Describe the
lung cancer
experience in
relation to
perceived
stigmatization,
smoking
behaviors,
and illness
causes;
Aim 2:
Discuss these
findings
relative to the
role of the
nurse as a
patient
advocate

Scott,
Crane,
Lafontaine,
Seale, and
Currow
(2015)

Qualitative/ Semi-structured ▪ 20 participants
Evaluate
interviews
stigma as a
▪ 60% male
barrier to
40% female
seeking
medical
▪ Ethnicity/race
attention
not reported
from the
perspective of
▪ 65% former
the lung
35% never
cancer
smokers
survivor and
health
(Australia)
professionals
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Emergent themes
included societal
▪ 45% male
attitudes; institutional
55% female
practices and
experiences; negative
▪ 100% Caucasian thoughts and
emotions such as
▪ Smoking status guilt, self-blame and
not reported
self-deprecation,
regret, and anger;
(USA/Midwest)
actual stigmatization
experiences; smoking
cessation; personal
choices versus
addiction; and causal
attributions

▪ Lung cancer
survivors reported
stigmatization and
blame for acquiring
the disease secondary
to tobacco
▪ Anti-smoking ads
perpetuate the stigma
▪ Health-care
professionals
indicated placing a
sense of responsibility on the survivors
partly due to the
“choice” of smoking

Study

Design/
Aim(s)

Participants
(Setting)

Method

Jeong,
MetaJeong, and synthesis/
So (2016)
Explore and
synthesize the
experience of
stigma among
lung cancer
survivors in
qualitative
studies

Review of
qualitative
studies utilizing
the process
according to
Sandelowski
and Barroso
(2007)

7 qualitative
studies

Liu et al.
(2016)

Qualitative
(exploratory)
study utilizing
semi-structured
individual
interviews to
obtain data and
analyze

▪ 17 participants

Qualitative/D
escribe
experiences
of lung
cancer
survivors in
China relative
to stigma and
coping
strategies

(3 USA, 3 United
Kingdom, 1
Australia)

▪ 59% male
41% female
▪ Ethnicity/race
not reported
▪ Smoking status
not
reported
(China)

Rowland et Qualitative/
al. (2016)
Explore QOL
and support
experiences
among
individuals
with
advanced

Semi-structured ▪ 9 participants
interviews were
analyzed using ▪ 67% male
interpretative
33% female
phenomenological analysis
▪ 67% former
33% current
39

Results/Findings
Themes synthesized
included:
Experiencing some
distance from the
surrounding world;
experiencing selfmade distance
between the disease
and oneself; the
disease experience
causes social
isolation and
loneliness; and there
is a lack of
supportive care for
myself
3 themes identified:
(1) sources of
stigma—smoking,
decreased
functioning, damage
to self-image; (2)
experience of stigma,
perceived
discrimination, social
isolation; (3) coping
with stigma—
concealment, giving
explanation about
disease, cooperation
with medical
professionals,
disclosing
dissatisfaction with
discrimination
▪ Themes identified:
effect of illness on
QOL—depended on
how physical tasks
are achieved; family
support—good but
experienced
changing roles;

Study

Design/
Aim(s)

Participants
(Setting)

Method

lung cancer

Results/Findings

smokers

coping strategies
were varied; medical
▪ Race/ethnicity
support
not reported
communication was
challenged, and
(United Kingdom) smoking status
predicted this at
times; smoking—
social stigma,
acknowledgement of
etiology related to
diagnosis
QUANTITATIVE STUDIES

LoConte,
Else-Quest,
Eickhoff,
Hyde, and
Schiller
(2008)

Quantitative/
Evaluate guilt
and shame in
non-smallcell lung
cancer
patients in
comparison
to breast and
prostate
cancer

Repeated
measure surveys
at three time
points using
means to
evaluate
between
subjects;
multiple
analysis of
covariance.
stigma measured
with Perceived
Cancer Related
Stigma (nonvalidated
instrument) and
the State Shame
and Guilt Scale
(SSGS;
measures guilt
and shame)
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▪ 96 participants
▪ 51% male
49% female
▪ 94% White
2% Black
1% Native
American
1% Hispanic
▪ 11.5 % current
80% former
8% never
smokers
(USA/Midwest)

▪ Those with lung
cancer had a higher
level of perceived
stigma than
individuals with
breast and prostate
cancer
▪ Smokers overall
had a higher level of
shame and guilt,
anxiety, and
depression regardless
of cancer’s cause
▪ Guilt and shame
did not increase or
decrease over the
three time points for
all cancers

Study
Else-Quest,
LoConte,
Schiller,
and Hyde
(2009)

Cataldo,
Slaughter,
Jahan,
Pongquan,
and Hwang
(2011)

Design/
Aim(s)

Participants
(Setting)

Method

Quantitative/
Aim 1:
Assess cancer
patients’
experience of
stigma and
self-blame
after
diagnosis of
breast, lung,
and prostate
cancer;
Aim 2:
Explore
stigma,
shame, and
self-blame
(internal
attribution)
relative to
psychological
adjustment
(anxiety,
anger,
depression,
self-esteem,
and causal
attribution for
cancer)
among cancer
survivors

Bivariate and
multivariate
correlation
examining
differences
between the
cancer groups;
hierarchical
regression
examining
mediation
between selfblame and
perceived
stigma;
perceived
stigma measured
with Perceived
Cancer Related
Stigma (nonvalidated
instrument)
developed by
authors; causal
attribution
evaluated using
thematic content
analysis

▪ 96/172
participants with
lung cancer

Psychometric
analysis/
Develop and
evaluate an
instrument to
measure
perceived
stigma of
individuals
with lung
cancer

Exploratory
online survey
for factor
analysis for
construct
validity;
correlations to
establish
criterion-related
validity and
measure internal
consistency

▪ 186 participants
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▪ 51% male
49% female
▪ 94% White
3% African
American
2 % Native
American
< 1% Hispanic
▪ 92% current or
former smokers
(USA/Midwest)

▪ 30% male
70% female
▪ 86% White
8% Asian
2% Hispanic
3.2% Other
▪ 79% current
smokers

Results/Findings
▪ Strong correlation
between self-blame,
self-esteem, and
perceived stigma for
all participants
▪ Participants (all
cancers) who
reported internal
attribution had higher
self-blame, lower
self-esteem, higher
anxiety, and higher
depression
▪ Lung cancer
participants reported
more internal
attribution/behavioral
cause of disease

▪ The authors
validated the scale
that was developed to
measure components
of stigma
▪ 4 subscales
identified:
shame/stigma, social
isolation,
discrimination,
smoking
▪ Associations

Study

Cataldo,
Jahan, and
Pongquan
(2012)

Design/
Aim(s)

Quantitative/
Aim 1:
Examine the
relationship
of LCS,
depression,
and QOL;
Aim 2:
Explore
impact of
LCS on QOL,
adjusting for
age, gender,
smoking
status, and
depression

Participants
(Setting)

Method

Results/Findings

reliability of
CLCSS

21% non-smokers between perception
of LCS and
(USA/38 states)
depression, QOL,
social support and
conflict, and selfesteem

Online
questionnaire
examining the
association
between selfreported LCS
and depression
and QOL, with
comparison
between lung
cancer
participants who
were smokers
and nonsmokers using
CLCSS

▪ 190 participants
▪ 56% male
43% female
▪ 85% Caucasian
1.5% African
American
8.4% Asian or
Pacific Islander
1.5% Hispanic
0.5% American
Indian
1% More than
one ethnicity

▪ Positive
relationship between
LCS and depression
▪ Inverse relationship
between LCS and
QOL
▪ LCS significantly
contributed to the
explanation of QOL
▪ Small difference
between ever
smokers* and never
smokers

▪ 80% ever*
20.5% never
smokers
(USA)
Chambers Systematic
et al. (2012) review/
Assess the
influence of
stigma and
nihilism on
lung cancer
care QOL and
psychosocial
well-being

The search was ▪ 15 articles
guided by
reviewed and
stigma and
discussed:
medical
7 qualitative
treatment
8 quantitative
outcomes,
psychosocial
outcomes, and
public health
impact; assessed
LCS or nihilism
and included an
outcome of
interest relative
to survival,
delayed
42

▪ LCS has an adverse
effect on
psychosocial wellbeing and overall
QOL
▪ Felt, perceived, and
enacted stigma are
experienced by many
with lung cancer
▪ Did not find a clear
indication of nihilism
in association with
stigma

Study

Design/
Aim(s)

Participants
(Setting)

Method

Results/Findings

presentation,
treatment
adherence or
refusal, patterns
of care,
psychological
distress,
psychological
help seeking or
QOL
Gonzalez
and
Jacobsen
(2012)

Lebel,
Castonguay et al.
(2013)

Quantitative/
Examine
possible
association
between
perceived
stigma related
to a lung
cancer
diagnosis and
depressive
symptomatology

Quantitative/
Examine
cancer-related
stigma,
determinants,
and
psychosocial
impacts in
lung and head
and neck
cancer
survivors

Correlational
analysis from a
questionnaire
and selfreported
measures
assessing
perceived
stigma,
depressive
symptomatology, and a
chart review to
supplement this
information;
SIS-Stigma was
used

▪ 95 participants

Self-reported
questionnaires
for correlations
between stigma,
behavioral selfblame,
disfigurement,
illness
intrusiveness,
benefit finding,
distress, and
subjective wellbeing and
sociodemographic and
medical

▪ 107/206
participants with
lung cancer
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▪ Degree of
perceived stigma is
▪ 41% male
significantly related
59% female
to depressive
symptomatology
▪ 92.6% White▪ Poorer social
Caucasian
support, more
7.4% Non-White avoidant coping, and
more dysfunctional
▪ 15.7% current
attitudes were
71.5% former
significantly related
13.3% never
to greater depressive
smokers
symptomatology
(USA/Southeast)

▪ 40% male
60% female
▪ 12% current
79% former
8% never
smokers
▪ Ethnicity/race
not reported
(Toronto, Canada)

▪ Lung cancer
survivors had higher
self-blame and higher
stigma than head and
neck cancer survivors
▪Self-blame did not
predict stigma
▪ Stigma correlated
significantly and
positively with
distress and
negatively with wellbeing

Study

Design/
Aim(s)

Participants
(Setting)

Method

Results/Findings

variables;
hierarchical
multiple
regression to
predict the
impact of stigma
on distresses and
well-being;
stigma by cancer
site, age, selfblame, and
disfigurement;
measured stigma
with 13-item
sub-scale from
the Explanatory
Model Interview
Catalogue
Lebel,
Quantitative/ Correlational
Feldstain et Examine
analyses were
al. (2013)
cancer-related conducted
stigma,
examining the
determinants, associations
and
between positive
psychosocial health changes
impacts in
Sociodemolung and head graphic and
and neck
medical
cancer
variables.
survivors and Hierarchical
its
multiple
relationship regression to
to positive
examine the
health
predicted power
changes
of stigma, selfblame, age,
radiation
treatment, and
smoking status
in relationship to
positive health
changes.
Utilized 13-item
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▪ 107/206
participants, lung
cancer survivors
▪ 40% male
60% female
▪ 12% current
79% former
8% never
smokers

▪ In comparison to
other cancer
survivors, lung
cancer survivors
experienced higher
levels of stigma and
self-blame, and lower
positive health
changes

▪ Behavioral selfblame significantly
▪ Ethnicity/race
predicted adoption of
not reported
positive health
changes whereas
(Toronto, Canada) stigma did not

Study

Design/
Aim(s)

Participants
(Setting)

Method

Results/Findings

sub-scale from
the Explanatory
Model Interview
Catalogue to
measure
perceived
stigma.
CarterPsychometric Self-reported,
Harris and analysis/
written surveys
Hall (2014) Aim 1:
followed by
Investigate
semi-structured
the
interviews;
dimensionprinciple
ality of the
component
original
analysis used to
CLCSS in a assess
sample of
dimensionality
lung cancer
followed by
patients;
exploratory
Aim 2:
factor analysis;
Evaluate
reliability tested
internal
using Cronbach
consistency
alpha
reliability of
the original
CLCSS;
Aim 3:
Shorten the
CLCSS using
exploratory
factor
analysis and
reliability
indicators

▪ 94 participants

CarterHarris,
Hermann,
Schreiber,
Weaver,
and Rawl
(2014)

▪ 93 participants

Quantitative/
Examine
relationships
among
demographic
variables,
health-care
system
distrust, lung

Cross-sectional,
correlational
study using selfreported surveys
followed by
semi-structured
interview;
CLCSS used to
measure stigma
45

▪ 38% male
62% female
▪ 83% White
17% African
American
▪ 68% ever*
32% never
smokers

▪ 3 factors identified:
shame and blame;
social isolation;
discrimination
▪ Scale decreased to
21 from 31 items
with internal
consistency of .93
(compared to .95 for
the 31-item scale)

(USA/Southern
Midwest)

▪ 38% male
62% female
▪ 83% Caucasian
17% African
American

▪ Associations
present among time
from symptom onset
to medical help,
health-care system
distrust, LCS,
smoking status,
income, ethnicity,
and social

Study

Design/
Aim(s)

Participants
(Setting)

Method

▪ 32% current
35% former
32% never
smokers

cancer,
stigma,
smoking
status, and
timing of
medical care
BrownJohnson,
Brodsky,
and
Cataldo
(2014)

Quantitative/
Investigate
LCS anxiety,
depression,
and QOL
among ever*
and never
smokers

(USA/Southern
Midwest)
Descriptive
cross-sectional
study;
correlational
analyses and
hierarchical
multiple
regression were
performed using
multiple surveys
for anxiety,
depression, and
QOL; CLCSS

▪ 149 participants
▪ 25% male
75% female
▪ 93% Caucasian
7% NonCaucasian
▪ 80% ever*
20% never
smokers
(USA)

Yang, Liu,
Yang, Ji,
and Li
(2014)

Psychometric
analysis/
Test
reliability and
validity of the
Chinese
version of
CLCSS for
lung cancer
survivors

Exploratory
factor analysis;
correlational
design for
construct
validity;
Cochran’s alpha
for reliability

▪ 117 participants
▪ 74% male
26% female
▪ Ethnicity/race
not reported

Results/Findings
desirability
▪ LCS was a
significant predictor
of increased time
from symptom onset
to seeking medical
help
▪ Significant negative
relationships between
QOL, and anxiety
and depression, and a
significant negative
relationship between
LCS and total QOL
▪ Significant
associations with
LCS and three of the
four QOL subscales
(physical,
psychological, and
social well-being)
▪ Smoking status did
not affect LCS,
depression, or QOL
▪ Negative
association between
all stigma factors and
self-esteem
▪ Positive association
between all stigma
factors and
depression

▪ Smoking status
not reported
(China)

Chambers, Quantitative/ Cross-sectional
Baade et al. Describe the survey
(2015)
impact of
examining
stigma on
psychological
lung cancer
distress and
patients’
QOL after
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▪ 151 participants
▪ 52% male
48% female
▪ 72% Australia-

▪ An increase of
stigma, shame, and
discrimination was
associated with
increased anxiety
▪ A higher level of

Study

Design/
Aim(s)

Participants
(Setting)

Method

psychological diagnosis of
distress and lung cancer;
QOL
health-related
stigma, social
constraints, and
illness
appraisals were
assessed as
predictors of
adjustment
outcomes;
surveys
measured
psychological
distress
(depression and
anxiety), QOL,
social
constraints, and
stigma (using
CLCSS);
hierarchical
regression used
Chambers, Mixed
Morris et methods/
al. (2015)
Test the
acceptability
of a focused
cognitive
behavioral
intervention
targeting
stigma for a
group of
patients with
lung cancer

Intervention was
a 6-week
telephone selfhelp
intervention—
stigma, QOL,
depression, and
cancer-related
distresses were
measured prior
to the
intervention for
baseline and in
months after
study began;
interview with
participants
completed at 3
months to assess
acceptability of
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born
28% Other
▪ Specific
race/ethnicity not
reported
▪ 83% ever*
17% never
smokers
(Australia)

▪ 25 participants
▪ 12% male
88% female
▪ Ethnicity/race
not reported
▪ 28% current
52% former
20% never
smokers
(Australia)

Results/Findings
shame related to
stigma was
associated with
increased depression
▪ An association
between stigma, and
shame and distress,
was established; also,
stigma and shame
had a significant
association with
QOL

▪ Overall stigma
score decreased at
the second time
point; the subscale of
discrimination did
not have a substantial
change
▪ Psychological
outcomes also
improved
▪ Stigma was a theme
identified from the
interviews postintervention

Study

Design/
Aim(s)

Participants
(Setting)

Method

Results/Findings

the intervention;
stigma measured
with CLCSS
Gonzalez et Quantitative/ Correlational
al. (2015)
Examine lung design to
cancer
evaluate
diagnosis
demographics
concealment and clinical
and its
variables with
association
concealment of
with LCS,
cancer
social anxiety diagnosis;
and social
hierarchical
avoidance,
regression
coping
analysis to
strategies,
predict
support
concealment;
systems,
SIS-Stigma used
anxiety and
depression,
and selfesteem

▪ 117 participants

Shen et al.
(2015)

▪ 141 participants

Quantitative/
Aim 1:
Examine
posttraumatic
growth
among lung
cancer
survivors as a
potential
buffer against
the
relationship
between
stigma and
psychological
distress;
Aim 2:
Examine how
these
relationships

Hierarchical
linear regression
utilizing
multiple surveys
on
psychological
distress stigma,
post-traumatic
growth, and
demographics;
Shame and
Stigma scale
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▪ 50% male
50% female
▪ 82% Caucasian
18% NonCaucasian
▪ 78% ever*
22% never
smokers
(USA/Southeast)

▪ 26% of participants
concealed their
diagnosis
▪ Strong association
between concealment
and internalized
shame
▪ Anxiety,
depression, cancerspecific distress,
social avoidance, and
self-esteem not
associated with
diagnosis
concealment

▪ LCS significantly
associated with
▪ 38% male
psychological
62% female
distress
▪ High levels of post▪ 95% Caucasian traumatic growth
3% African
among pre-diagnosis
American
smoking quitters;
however, higher
▪ 70% former pre stigma levels were
diagnosis smoking associated with
quitters
higher levels of
30% former post- psychological
diagnosis quitters distress
20% never
▪ Among postsmokers
diagnosis quitters,
stigma was
(USA/Northeast) associated with
higher levels of
psychological
distress at low levels

Study

Design/
Aim(s)

Participants
(Setting)

Method

differed by
the timing of
quitting
smoking
Criswell,
Owen,
Thornton,
and
Stanton
(2016)

Shen,
Hamann,
Thomas,
and Ostroff
(2016)

Psychometric
analysis/
Evaluate
Cancer
Responsibility and Regret
Scale

Quantitative/
Evaluate
patientprovider
communication and its
association
with LCS

Results/Findings
of post-traumatic
growth

Factor analysis
of the scale,
which measures
the constructs of
medical stigma,
personal
responsibility,
and regret;
correlational
design to
compare
measures among
never smokers,
former smokers,
and current
smokers

▪ 213 participants

Surveys
completed by
participants on
tablet computer
through a secure
electronic (webbased) portal,
using their own
computer, or a
paper-based
version of the
survey; stigma
measured with
CLCSS;
bivariate
correlations and
multivariate
regression
assessed
association and

▪ 231 participants
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▪ 44% male
56% female
▪ 80% Caucasian
18% Other
▪ 18% current
66% former
16% never
smokers
(USA/Western)

▪ 36% male
64% female
▪ 79% Caucasian
14% African
American
▪ 9% current
65% former
26% never
smokers
(USA/Multisite
recruitment)

▪ Current and former
smokers had higher
personal
responsibility and
regret than never
smokers
▪ All smoking
statuses reported
medical stigma with
very little difference
between
current/former
smokers and never
smokers; greater
medical stigma was
associated with
worsening
psychological
functioning
▪ Good patientprovider
communication is
associated with lower
stigma
▪ Age and marital
status were
significantly
associated with
stigma
▪ No association
between smoking
status and LCS

Study

Design/
Aim(s)

Participants
(Setting)

Method

Results/Findings

significance of
stigma, patientprovider
communication,
and smoking
status
Hamann,
Shen,
Thomas,
Lee, and
Ostroff
(2017)

Psychometric
analysis/
Evaluate
newly
developed
LCSI

▪ 231 participants

Exploratory
factor analysis
on phase III
participants of
this study; 25item survey
developed and
validated

▪ 36% male
64% female
▪ 79% Caucasian
14% African
American

▪ Internal consistency
0.89; convergent
validity (CLCSS) r =
.58
▪ Three factors
identified: internal
stigma, perceived
stigma, constrained
disclosure

▪ 8% current
65% former
26% never
smokers
(USA/South)
So, Chae,
and Kim
(2017)

Psychometric
analysis/
Evaluate
reliability and
construct
validity of the
Korean
Cancer
Stigma Scale
(adapted from
CLCSS)

▪ 50/247
participants with
lung cancer

Exploratory
factor analysis
and construct
validity
performed

Factors identified:
social isolation,
distancing/
avoidance,
▪ 40% of 247 male discrimination, guilt,
60% of 247
attribution, lack of
female
medical support
▪ Ethnicity/race
not reported
▪ Smoking status
not reported
(South Korea)

Weiss et al. Quantitative/ Phone and
(2017)
Understand
online surveys
lung cancer
administered to
survivors’
evaluate
experiences perceived
and attitudes stigma, self-
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▪ 174 participants
▪ 52% male
48% female
▪ 91% Caucasian

▪ Stage III
participants (43% of
all in study) indicated
a high level of
perceived stigma
from society as a

Study

Design/
Aim(s)
toward
stigma, selfblame, and
medical care
satisfaction

Participants
(Setting)

Method

blame, and
9% Other
satisfaction of
care;
▪ 19% current
correlational
68% former
design used to
13% never
assess
smokers
associations
with these
(USA)
factors and
demographic
characteristics;
non-validated,
63-item survey
developed by
Health
Communication
Company

Results/Findings
whole
▪ Low correlation
between stigma and
self-blame; current
and former smokers
were more likely to
report self-blame,
and smoking history
was strongly
correlation with
stigma

Note. Studies are presented in chronological order of publication (and then in alphabetical order for
publications from the same year). LCS = lung cancer stigma; QOL = quality of life; SIS = Social Impact
Scale; CLCSS = Cataldo Lung Cancer Stigma Scale; PSS = Perceived Stigma Scale; LCSI = Lung Cancer
Stigma Inventory.
* An ever smoker is one who either currently smokes or previously smoked in the past.
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Table 2.2 Scoping Literature Review Instruments Assessing Lung Cancer Stigma

Instrument

Authors
(Year)

Scoring
Dimensionality Procedure

Method(s)

Reliability
Coefficient
Alpha

Validity

Cataldo Lung BrownCancer Stigma Johnson,
Scale
Brodsky, and
Cataldo
(2014);
Carter-Harris
and Hall
(2014);
CarterHarris,
Hermann,
Schreiber,
Weaver, and
Rawl (2014);
Cataldo,
Jahan, and
Pongquan
(2012);
Cataldo,
Slaughter,
Jahan,
Pongquan,
and Hwang
(2011);
Chambers,
Baade et al.
(2015);
Chambers,
Morris et al.
(2015); Shen,
Hamann,
Thomas, and
Ostroff
(2016); So,
Chae, and
Kim (2017);
Yang, Liu,
Yang, Ji, and
Li (2014)

Exploratory
factor analysis
yield, 4
domains:
stigma and
shame, social
isolation,
discrimination,
smoking

Balanced
31-item
Likert 4point
scale: 1 =
Strongly
Agree; 4 =
Strongly
Disagree

Psychometric
testing: internal
consistency,
construct
validity, and
criterion
validity;
additional
analysis
included
correlations,
multiple
regression

Total Scale:
0.96; for
each
domain—
stigma and
shame: 0.97;
social
isolation:
0.97;
discriminati
on: 0.92;
smoking:
0.74

Criterionrelated
validity
supported
by
correlation;
predicted
direction of
association
with similar
constructs:
depression,
QOL, social
support,
social
conflict,
self-esteem

Cancer
Responsibility
and Regret
Scale

Exploratory
factor analysis
yield, 3
domains:
personal
responsibility,
regret, medical
stigma

Balanced
23-item 7point
Likert
scale

Factor analysis,
correlational
analysis, and
multiple linear
regression

Personal
responsibility: 0.84;
regret: 0.64;
medical
sigma: 0.71

Construct
validity
done with
Pearson
correlation
with
measure
from similar
constructs

Criswell,
Owen,
Thornton,
and Stanton
(2016)
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Instrument

Authors
(Year)

Scoring
Dimensionality Procedure

Method(s)

Reliability
Coefficient
Alpha

Validity

Explanatory
Model
Interview
Catalogue

Lebel,
Castonguay
et al. (2013);
Lebel,
Feldstain et
al. (2013)

13-item
subscale
adapted from
interview to
questionnaire

Balanced
13-item
Likert 4point scale
based on
agreement
of
statement

Correlational
and hierarchical
multiple
regression

0.82

Not
assessed

Lung Cancer
Stigma
Inventory

Hamann,
Shen,
Thomas, Lee,
and Ostroff
(2017)

Exploratory
factor analysis
yield, 3 factors:
internalized
stigma,
perceived
stigma,
constrained
disclosure

Balanced
25-item
Likert 5point
scale: 1 =
Not at All;
5=
Extremely

Preliminary
psychometric
testing; internal
consistency;
test-retest
correlation and
convergent
validity

0.89; testretest
correlation r
= 0.91

Convergent
validity with
CLCSS was
r = .58

Perceived
Stigma Scale

LoConte,
Not assessed
Else-Quest,
Eickhoff,
Hyde, and
Schiller
(2008); ElseQuest,
LoConte,
Schiller, and
Hyde (2009)

Balanced
6-item
Likert 5point
scale: 1 =
Strongly
Agree; 5 =
Strongly
Disagree

Repeated
measures of
stigma, guilt,
and shame

0.75

Not
assessed

Shame and
Stigma Scale

LoConte et
al. (2008);
Shen et al.
(2015)

Exploratory
factor analysis
yield for
original scale,
4 domains:
shame with
appearance,
sense of
stigma, regret
and speech,
social concerns

Balanced
20-item
Likert 5point
scale: 1 =
Never; 5 =
All the
Time

Internal
consistency for
adaption for lung
cancer; bivariate
correlations with
stigma and other
related variables
and hierarchical
linear regression
between stigma,
anxiety, and
depression,
controlling for
demographics

Total (2
domains):
0.81
(internal
stigma
domain:
0.77;
perceived
stigma
domain:
0.79)

Construct
validity with
preliminary
psychometric
testing with
Pearson
correlation
with similar
constructs

Social Impact
Scale

Gonzalez and
Jacobsen
(2012);
Gonzalez et
al. (2015)

Factor analysis
yield, 4
domains: social
rejection,
financial
insecurity,
internalized
shame, social
isolation

Balanced
24-item
Likert 4point scale

Correlational
design and
hierarchical
linear regression

0.95

Construct
validity
tested
previously
and
established

53

163 ARTICLES RETRIEVED IN INITIAL SEARCH

Web
of Science
n = 59

CINAHL
n = 43

PubMed
n = 35

PsycINFO
n = 26

114 articles deleted from search due to duplication
between databases

19 articles deleted due to:
Aims not specific to stigma and lung cancer
Commentary article or meeting abstract

30 articles included in this scoping review

Figure 2.1 Sample Selection Process
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CHAPTER 3:
EVALUATION OF LUNG CANCER STIGMA WITH THE CATALDO LUNG
CANCER STIGMA SCALE AMONG AFRICAN AMERICAN SURVIVORS OF
LUNG CANCER IN SOUTH CAROLINA2

2

Webb, L. A., McDonnell, K. K., Adams, S. A., Davis, R. E., Donevant, S., and Felder, T. M. To be

submitted to the Journal of Psychosocial Oncology.
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Abstract
Purpose:
To evaluate the reliability and validity of the Cataldo Lung Cancer Stigma Scale
(CLCSS) and to explore its interpretation among African Americans in South Carolina.
Research Approach:
Multiple methods, utilizing correlational and thematic analysis.
Sample:
A purposive sample of 26 African Americans, who completed self-report surveys.
Ten participated in one-to-one interviews.
Findings:
Participants reported a moderate level of lung cancer stigma, depressive
symptoms, and quality of life (QOL). Depressive symptoms were positively associated to
lung cancer stigma, and QOL was negatively associated to lung cancer stigma. Thematic
analysis revealed social isolation, regrets, and discrimination.
Conclusions:
The CLCSS was a reliable instrument for evaluating LCS among this sample of
African Americans. However, further evaluation of the CLCSS is needed to assess
cultural considerations among African Americans. Depressive symptoms and lung cancer
stigma share a link and may contribute to better understanding of QOL among African
American lung cancer survivors.
Implications for Psychosocial Providers:
Lung cancer stigma manifests itself differently among individuals, races, and
ethnicities. It is important for health professionals to acknowledge and have awareness of
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the presence of lung cancer stigma and the negative ramifications that it has on overall
QOL, including physical, mental, and social well-being. An evaluation of this healthrelated stigma, depression, and QOL should be considered when planning individualized
care for survivors of lung cancer, particularly African Americans.
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Introduction
Although there have been advances in early detection and treatment modalities,
lung cancer remains the leading cause of cancer and cancer deaths among both men and
women in the United States (American Cancer Society [ACS], 2019). In 2018, the ACS
estimated over 224,000 diagnoses of lung cancer with approximately 142,000 deaths
from the disease. Individuals living with lung cancer experience greater levels of
psychological distresses in comparison to other cancer survivors (Brown Johnson et al.,
2015; Chambers, Baade et al., 2015; Chapple, Ziebland, & McPherson, 2004; Gonzales
& Jacobsen, 2012; Hamann et al., 2014). Psychological challenges such as depression
and anxiety experienced by survivors may worsen shortness of breath, pain, and insomnia
as well as lead to social isolation and loneliness (Chambers, Baade et al., 2015). Lung
cancer stigma (LCS) is a formidable challenge among survivors that may affect many
aspects of life (Cataldo, et al., 2011; Cataldo, Jahan, & Pongquan, 2012).
Lung cancer stigma is a complex, intertwining phenomenon associated with the
behavior of cigarette smoking (Brown-Johnson, Brodsky, & Cataldo, 2014). Cigarette
smoking is a contributory factor in the development of debilitating chronic diseases and
is an environmental health hazard (U.S. Department of Health and Human Services
Public Health Office of the Surgeon General [OSG], 2014). Anti-smoking campaigns
have resulted in ostracization of smokers who continue this behavior despite the health
warnings (Bayer, 2008). This characterization occurs in a health-related stigma when
lung cancer survivors are categorized and viewed with shame and blame (Hamann et al.,
2014). Lung cancer stigma is characterized by negative and victim blaming perceptions
of cigarette smoking and a lung cancer diagnosis, and verbiage or actions of others that,
in turn, exacerbate psychological distresses, negatively influence QOL, and contribute to
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the layered effect of stigma for individuals with lung cancer (American Lung Association
[ALA], 2014; Daher, 2012; Lebel, Castonguay et al., 2013). This layered stigma affect
may yield feelings of stigma and shame for lung cancer survivors. It may also contribute
to social isolation which affects mental and physical symptom burden (Brown-Johnson et
al., 2014; Carter-Harris & Hall, 2014; Cataldo et al., 2011).
African Americans experience a significant disparity in lung cancer incidence and
survival rates. In 2017, there were 24,000 lung cancer diagnoses among African
Americans and over 17,000 deaths resulting from this disease (ACS, 2016). The overall
5-year relative survival rate for lung cancer is lower in African Americans in comparison
to Caucasians: 14% versus 18%, respectively (ACS, 2016). In the state of South Carolina,
African Americans males have a higher age-adjusted incidence of lung cancer (88%) and
a lower survival rate (13.4%) compared to Caucasian males (78.8% incidence, 15.5%
survival rate). By contrast, African American women have a lower age-adjusted lung
cancer incidence (39%) and survival rate (19.1%) compared to Caucasian women (56.1%
and 21.6%, respectively) (CDC, 2018). This cancer disparity is disconcerting for the
African American community.
Many factors influence lung cancer outcomes among African Americans. Lack of
access to quality health care resulting in delayed diagnosis, fewer options offered at the
time of diagnosis, limited treatment choices, and cancer risk behaviors are a few possible
factors involved with the disparate survival rates (Park et al., 2011). African Americans
living with lung cancer have higher rates of depressive symptoms than Caucasian lung
cancer survivors (Traeger, Cannon, Pirl, & Park, 2013). This may be caused in part by
individuals continuing a behavior that has contributed to the disease state, as well as less
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compassion and support from others compared to those who contract and live with other
types of cancer, such as breast and prostate (Traeger et al., 2013). Stigma (perceived or
experienced, or both) is another variable which negatively impacts this vulnerable
population of cancer survivors (Cataldo et al., 2011; Chambers et al., 2012; Chapple et
al., 2004; Gonzales & Jacobsen, 2012; Hamann et al., 2014). Stigma may be influenced
by individuals attributing a lung cancer diagnosis to cigarette smoking, whereas other
cancers may be thought to occur by factors outside of a person’s control (Else-Quest,
LoConte, Schiller, & Hyde, 2009).
To date, there is limited research on lung cancer stigma among African
Americans. Investigating the ramifications of lung cancer stigma in this vulnerable
population will add to the body of knowledge about lung cancer survivorship and provide
evidence that may assist with development of interventions to mitigate the negative
influences of stigma and improve survival rates as well as QOL.
The Cataldo Lung Cancer Stigma Scale (CLCSS), adapted in 2011 from Berger’s
HIV stigma scale, is the first validated health-related stigma instrument specifically for
lung cancer survivors (Cataldo et al., 2011). This instrument evaluates perceived stigma
with four domains: stigma and shame, discrimination, social isolation, and smoking. To
date, this instrument has demonstrated content and construct validity among primarily
Caucasian samples in the United States (Brown-Johnson et al., 2014; Cataldo et al., 2011;
Cataldo et al., 2012; Hamann, Shen, Thomas, Lee, & Ostroff, 2017; Shen, Hamann,
Thomas, & Ostroff, 2016). To continue to add to the body of evidence related to lung
cancer stigma, it is warranted that the CLCSS be evaluated among African American
lung cancer survivors.
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Study Aims and Hypotheses
The aims of this study are to evaluate: (1) the internal consistency reliability, and
construct validity of the CLCSS among African American lung cancer survivors in South
Carolina, and (2) explore the experiences and interpretations of the CLCSS among this
sample of survivors of lung cancer.
The following hypotheses will be tested:
1. The CLCSS will demonstrate internal consistency among this population of lung
cancer survivors, with a Cronbach’s alpha of greater than 0.7.
2. Construct validity will be supported by a positive correlation between lung cancer
stigma and depressive symptoms and a negative correlation between lung cancer
stigma and QOL.
Methods
This study was guided by an adapted conceptual model of lung cancer stigma
originally developed by Cataldo et al. (2011). This adapted model posits that lung cancer
survivors perceive societal attitudes related to smoking and a lung cancer diagnosis. The
survivor is aware of potential or actual behaviors exhibited by others, and this perception
prompts certain feelings, such as the feeling of stigma and shame. The perceptions and
feelings of the survivor are associated with depression, which affects QOL and survival
rates. (See Figure 3.1.)
To address the aims, a multiple-method approach was used. Quantitative methods
included correlational analysis to determine the linear direction and to quantify
relationships between LCS and depression and LCS and QOL. Concurrently, a qualitative
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approach was used to evaluate the experiences of LCS and the understanding and
interpretation of the CLCSS amongst this sample.
Participant Selection, Recruitment, and Ethical Considerations
Participants were eligible and recruited for the study if they were age 21 years or
older, had a personal history of lung cancer, could speak and read English, and were an
African American resident of South Carolina. After Institutional Review Board (IRB)
approval from the study sites, a purposive sample of 26 African American participants
was recruited from three sources: a cancer registry of an accredited American College of
Surgeons cancer program; the Breathe Easier Club, a support group for lung cancer
survivors; and an ambulatory cancer treatment center. The primary recruitment method
was an IRB-approved recruitment letter and flyer that were mailed to potential
participants explaining the purpose and procedure of the study. Over a 4-month period,
137 invitations were mailed to African Americans survivors of lung cancer, and a
telephone call followed the mailing within 1–2 weeks. Potential participants had the
option of having the surveys mailed to them, administered via telephone, or administered
in person at a convenient location. The secondary recruitment method was a face-to-face
meeting with survivors who were in attendance at the Breathe Easier Club meeting. The
third recruitment strategy involved placing recruitment flyers in strategic areas at an
ambulatory cancer treatment center and approaching survivors during their appointments.
Each participant received a $20 gift card as a thank you gift.
Concurrent with quantitative data collection, a subset of the survey respondents
was recruited to participate in a 30- to 60-minute, semi-structured interview about their
interpretation of the CLCSS and their experience with LCS. The subset of participants
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was chosen according to the principle of maximum variation to achieve diversity
according to their gender, education, lung cancer stage, and time of diagnosis (Creswell,
2013). Each participant received an additional $10 gift card for completion of the
interview
Instruments
Demographic Characteristics
All participants completed an investigator-developed demographic form, which
collected information such as gender, age, annual household income, cancer diagnosis
year, self-reported health status, smoking status, educational attainment, and employment
data.
Stigma
The CLCSS is a 31-item, 4-point Likert scale that evaluates stigma. The original
psychometric testing was conducted by Cataldo et al. (2011). Exploratory factor analysis
identified four domains: stigma and shame, social isolation, discrimination, and smoking.
The original psychometric testing was conducted on an online sample that consisted of
primarily Caucasian participants (86%), without African American representation
(Cataldo et al., 2011). This original psychometric evaluation yielded excellent internal
consistency (Cronbach’s alpha = .97), and construct validity was determined with
correlational analysis among similar variables—depression, QOL, anxiety, and social
isolation (Cataldo et al., 2011). CLCSS scores range from 31 (low stigma) to 124 (high
stigma).
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Depression
The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item
self-report scale. This instrument has shown to be reliable across gender, race, and age
(Radloff, 1977). It has a high internal consistency, ranging from .85 to .90 (Radloff,
1977). This nondiagnostic instrument has multiple domains of depression, which include
depressed mood, feelings of guilt and worthlessness, feelings of helplessness and
hopelessness, psychomotor retardations, loss of appetite, and sleep disturbance. Scores
for this instrument are 0 (low depressive symptoms) to 60 (high depressive symptoms). A
score equal to or above 16 indicates depression. Depression, particularly the feeling of
guilt, is associated with this lung cancer stigma (Brown-Johnson et al., 2014).
Quality of Life
The European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire Core (EORTC QLQ-C30) measures QOL in individuals diagnosed with
cancer. The 13-item supplement for lung cancer was used for this study. This instrument
was tested on lung cancer patients and yielded an acceptable internal consistency of .70
(n = 110). Criterion validity was supported by correlation with clinical parameters that
addressed all domains of the scale (Nicklasson & Bergman, 2007). This study focused on
participants’ global health, indicating overall QOL of the cancer survivor. The score
range was 0 (low global health) to 100 (high global health). The mean global health score
for individuals with a lung cancer diagnosis is 56.6 (± 24.3). The influence from a healthrelated stigma has a negative impact on overall QOL. This is true in the case of lung
cancer stigma (Cataldo et al., 2011).
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Quantitative Analysis
Data were analyzed using SPSS Statistics Version 25.0. ® Descriptive statistics
were calculated to examine participants’ demographic characteristics and instrument
scores on LCS, depression, and global health. Global health was calculated using two
self-reported questions about participants’ health and QOL in the past week, and was
rated on a 7-item scale (1 = poor health/QOL, 7 = excellent health/QOL). Construct
validity of the CLCSS was evaluated using correlational analysis, which examined
association between LCS and depressive symptoms, and between LCS and global health.
Qualitative Analysis
Semi-structured interviews were audio-recorded and professionally transcribed
verbatim. The semi-structured interview guide contained questions designed to elicit
understanding of the terminology and meaning of the statements of the CLCSS. The PI
went over each statement of the CLCSS to gain this information (see Figure 3.2). The
recordings were reviewed for discussion elements and recall. Using an iterative approach,
two authors (LW, SD) independently coded the full transcripts line by line and searched
for salient themes. The two then met to compare codes, resolve any differences, and
identify themes. The researchers categorized the codes according to the CLCSS domains
and discussed specific quotes that represented the proposed themes. After conducting 10
interviews, it was determined that data saturation was reached, and the analysis was
finalized.
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Results
Participant Profile
The survey sample consisted of 26 African Americans (16 females, 10 males).
Participants’ average age was 67 years (SD = 8.9; range, 48–81). Half of the sample was
married with some college education. Participants’ lung cancer stages ranged from 1A to
4B, with over half diagnosed within the past 2 years. Over 60% rated their health as fair
to poor. Nineteen were former smokers, 4 were current smokers, and 3 never smokers
(see Table 3.1).
Of the 26 participants, 10 (6 females, 4 males) were chosen and consented to
participate in the one-to-one interviews. For this subsample, lung cancer stages ranged
from 1A to 3B, the average age was 67.3 (range: 62–74), and 40% had at least some
college education. Eighty percent reported their health as fair, 40% were married, and all
10 were retired or unable to work. All were former smokers, with number of years of
smoking ranging from 7 to 30.
Lung Cancer Stigma, Depression, and Global Health
Quantitative Results
The participants reported a mean stigma level of 57.8 (SD = 15.26) with a
possible range of 31–124, indicating a moderate level of perceived stigma. Cronbach’s
alpha was reported as .957 with an inter-item correlation mean of .447. The mean
depressive symptoms level reported was 17.6 (SD = 9.72; range: 0–60), indicating
moderately high depressive symptoms. The mean score for global health was 63.5 (SD =
25.61; range: 0–100), indicating modestly high overall QOL. (See Table 3.2.)
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Descriptive correlational analysis indicated a strong, statistically significant
positive association between depression and stigma (r = .494, p = .005). However, the
third hypothesis was not supported. There was a marginally significant negative
association between QOL and stigma (r = -.292, p = .074). It is important to note that
there is a significant strong negative association between depression and global health,
which was not a tested hypothesis but important for understanding the relationship
between these variables (r = -.746, p = .000). (See Table 3.3.)
Qualitative Results
Themes were categorized according to the four CLCSS domains (see Table 3.4).
The first domain is stigma and shame.
Theme 1: Not Feeling Guilty, but Regretting Smoking Cigarettes
In this sample, a few survivors expressed not feeling guilty but regretting ever
smoking cigarettes. They also thought it possible that others with their condition may feel
guilty, even though they personally did not feel this way. Here are some representative
responses:
“I don’t feel guilty. I don’t know why. I was the one that was diagnosed but I
don’t feel guilty. I just hate that it happened to me.”
“So, I knew—why I had cancer. I didn’t feel guilty but there may be other people
who never smoked and for some reason it bothers them to a guilty point. But I
can’t see a reason for people feeling guilty.”
“I don’t feel I deserved cancer. But I realize that if I hadn’t smoked my cancer or
not having lung cancer or maybe any kind of cancer would have been greater.”
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Theme 2: Transferring the Blame
Many interviewed participants expressed some conflicting thoughts about the
cause of their diagnosis. While they stated that they felt responsible for the development
of their diagnosis, they also pointed out that lung cancer is also caused by other factors.
“I personally don’t feel guilty for my— for my lung cancer because there are
other factors that go into it besides smoking.”
“I don’t think anybody . . . would feel guilty about having cancer. That’s
something you can’t control. Um—like, meaning it’s your fault.”
Interviewed participants (all former smokers) were inconsistent in their views of the
possible cause of their lung cancer, but all felt strongly that others need to know lung
cancer can be caused by other factors. This is evident by the following:
“Lung cancer doesn’t necessarily come from a cigarette. Lung cancer is not a
cigarette that you put in your mouth. Lung cancer can come from secondhand
smoke. And, I mean, that’s been said for years, but I guess when people started
getting cancer that didn’t smoke that’s when they realized that statement to be
true.”
“I don’t think that would be [that smoking causes lung cancer] . . . because
smokers and non-smokers have lung cancer. So, if someone thinks lung cancer is
only cause by cigarettes—it would just be someone who don’t have clear
understanding about lung cancer.”
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Theme 3: Feeling Isolated Because of Physical Limitations
A few participants expressed feeling social isolation because of their physical
limitations. Their conditions included shortness of breath, fatigue, and nausea, all of
which limited their physical functionality.
“I just don’t go to the things I used to because I don’t dance like I used to. I don’t
have the strength to do what I used to, and I can’t participate in the activities like
I used to.”
“I don’t spend no time around others, not like the way [I] used to—you know,
spend time there socializing. Well to some extent because I am not able to be out
there like that now. So, [I] have to walk in a different direction.”

Theme 4: Thinking Lung Cancer Is a Sentence to Death
When asked if others have distanced themselves from them because of their lung
cancer diagnosis, many participants did not indicate having this experience. However, a
few felt that others with their condition could possibly experience this situation. The
reason for the distancing, they explained, would be the thought of fatality related to the
diagnosis of lung cancer. Many of the participants were proud to point out that they were
surviving their diagnosis:
“Others may have that perception, that if you get lung cancer then you’re dead.
Yeah, and that is not the case—I’m living proof.”
“Cancer usually frightens people that you’re going to die. Not today. We are
survivors.”
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Theme 5: Putting Trust in God, Not Worrying About Being Judged by Others
The domain of discrimination yielded two more themes. Two participants plainly
stated it this way:
“At the end of the day, it’s just me and the Lord.”
“I don’t live my life for others to pick it apart.”
Theme 6: Lack of Trust/Fairness From Insurance Providers and Employers
The participants responded to statement related to discrimination from insurance
companies and employers. From their statements, it was clear that there is a lack of trust
among these entities.
“Employers—when I first started out in my career, would judge you as far as
weight, health problems, and they decide whether they was going to hire you or
not. Now here we are almost fifty years later, and it hasn’t improved; it’s gotten
worse.”
“I know a lot of jobs [where] they don’t have that blanket of protection for you so
there’s—you kind of like a big loss if you have no benefits to back you up.”
“Insurance companies are making decisions pertaining to our health depending
on your pocket.”
Theme 7: People Believing Lung Cancer Is Caused by Smoking
A few participants expressed that some people are more predisposed to lung
cancer, whether they smoked or not, and regardless of whether they stopped smoking
months or years prior to diagnosis. However, many participants noted that other people
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think that if a person has lung cancer, it must mean he or she once smoked or currently
smokes cigarettes. Many participants made a statement along these lines:
“Yeah, there’s a lot of people does think it comes from smoking, yes.”
“People tend to think that if you ever, ever smoked that that’s why you have lung
cancer.”
The authors’ aim was also to understand how African Americans interpreted the
statements in the CLCSS. This sample of African Americans demonstrated understanding
of 29 of 31 CLCSS items. The first exception was related to the one item regarding lung
cancer survivors being viewed as dirty. The other item regarded survivors feeling
unclean. In both instances the survivors expressed their opinions that uncleanliness is
related to physical symptoms; they did not think of it as referring to lung cancer as a dirty
disease related to cigarette smoking. They expressed similar comments about the
statement about feeling unclean. Participants also expressed concern that others need to
be educated to understand that lung cancer is not contagious, and they felt some people
may need education on all the causes of lung cancer.
Examining Quantitative and Qualitative Data
Utilizing multiple methods (i.e., collecting quantitative and qualitative data)
facilitated a deeper interpretation of the CLCSS. Quantitative data generated by the
instruments and qualitative data generated from the interviews were collected
concurrently, analyzed separately, and interpreted by combined results (Creswell, 2013).
These data displayed a moderate level of congruence between the quantitative and
qualitative data.
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Discussion
It was hypothesized that the CLCSS would prove to be a reliable instrument for
evaluating LCS in this sample of African American lung cancer survivors. The study’s
findings validate the first hypothesis (CLCSS internal consistency). Even though the
finding reported that the CLCSS was reliable for evaluating LCS, the instrument is
lengthy (31 items), and an original Cronbach alpha of .96 indicates redundancy among
items (Cataldo et al., 2011). Carter-Harris and Hall (2014) shortened the CLCSS to 21
items (yielded a Cronbach alpha of .93), lessening the burden on participants and
addressing the redundancies. This revised scale may be useful in future research inquiries
related to LCS.
This study evaluated the interpretations of the CLCSS among this sample. There
were two items the participants did not regard as stigma-related. An example was their
assumption that cleanliness related to physical symptoms rather than to the societal view
of cigarette smoking as a “dirty” habit. Although, these were the only two
misinterpretations of the CLCSS for this sample, there is a possibility that this may
extend to more statements of the scale among African American survivors of lung cancer.
This is a very important indication for future research. It is imperative that cultural
considerations, such as how instrument items are interpreted by African Americans, be
evaluated to fully understand the lung cancer experience.
Construct validity of the CLCSS was validated in this study (hypothesis 2). The
study found a statistically significant positive relationship between LCS and depression
as well as a statistically significant negative relationship between LCS and QOL. This is
consistent with previous findings on lung cancer survivors (Cataldo et al., 2011).
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African American cancer survivors historically have been underdiagnosed,
misdiagnosed, and undertreated related to depressive symptoms (Traeger et al., 2013).
This sample experienced a moderately large number of depressive symptoms. Feelings of
irritability and fatigue were prevalent in this sample. These symptoms overlap with
physical symptom burden, so it can be difficult to understand their true basis. This may
play a major factor in the underdiagnosis, misdiagnosis, and undertreatment of depression
among cancer survivors generally as well as African Americans specifically.
QOL was measured by self-reported global health, which including ratings of
quality of health and life. This sample reported a modestly higher health level than the
referenced mean for survivors of lung cancer. This was an unexpected finding. The
mixed methods approach assisted with understanding this finding. As displayed in the
interviews, the participants considered themselves fortunate to be living and thriving.
They considered their ability to fight this disease a success, and therefore they rated their
QOL as good to excellent even when their overall health status was fair to poor. The
study approach allowed the researchers to reach an inference that is strongly validated by
the combination of statistical data (on global health) and data from the interviews.
Depressive symptoms and QOL were statistically significant with a negative
association. This indicates that depressive symptoms and QOL impact each other, and
their relationship needs evaluation in order to plan and provide appropriate care to
survivors. It is important to note that QOL can be measured by many variables,
encompassing physical, social, and spiritual functioning. This sample of cancer survivors
suffered from multiple-physical-symptom burden, including shortness of breath,
insomnia, anxiety, and pain. Although these physical and psychological challenges were
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reported, the sample participants were generous with their overall input by reporting a
higher QOL level.
Conclusion
Lung cancer stigma was moderately experienced by this sample of African
American lung cancer survivors. This was indicated by the amount of stigma measured
and reported from the CLCSS as well as from the semi-structured interviews. This
research approach promoted deeper understanding of how members of this understudied
population of lung cancer survivors view stigma, while also adding to the larger body of
evidence regarding lung cancer survivors. An evaluation of stigma, depression, and QOL
may be warranted when planning individualized care for African American lung cancer
survivors. More research is needed to develop practical strategies to measure these
variables. Additional evaluation of cultural considerations is warranted among African
Americans and the CLCSS.
Limitations
To the best of our knowledge, this is the first study focused on African Americans
and the evaluation of lung cancer stigma. Although this study provides new evidence, it
represents a small sample in only one region of the United States.
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Table 3.1 Descriptive Statistics of Demographics and Health Status
Characteristic

Categories/description

Mean (SD)

Age

Range: 48–81

67.2

Gender

Male
Female

10 (38.5)
16 (61.5)

Education

High school graduate/some
college

18 (69.2)

Work status

Retired/unable to work

22 (84.6)

Self-reported health

Fair to poor

17 (65.4)

Year diagnosed

2016 and after

14 (54.8)

Smoking status

Never smoker
Current smoker
Former smoker

3 (11.5)
4 (15.3)
19 (73.2)
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Table 3.2 Descriptive Statistics for Lung Cancer Stigma, Depression, and Global
Health/Quality of Life

Instrument

Mean

Standard
deviation

Sample
range

Possible
range

CLCSS

57.8

15.3

35–94

31–124

CES-D

17.6

9.7

4–37

0–60

EORTC QLQ-C30

63.5

25.6

0–100

0–100

Note. CLCSS = Cataldo Lung Cancer Stigma Scale; CES-D = Center for
Epidemiologic Studies Depression Scale; EORTC QLQ-C30 = European
Organization for Research and Treatment of Cancer Quality of Life Questionnaire
Core.
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Table 3.3 Correlational Analysis with Pearson Product

Measure (Instrument)

Lung cancer
stigma (CLCSS)

Lung cancer stigma
(CLCSS)

Depressive symptoms
(CES-D)
.494*

Depressive symptoms
(CES-D)

.494*

Global health, QOL
(EORTC QLQ-C30)

-.292

Global health,
QOL (EORTC
QLQ-C30)
-.292

-.746*

-.746*

Note. CLCSS = Cataldo Lung Cancer Stigma Scale; CES-D = Center for Epidemiologic Studies
Depression Scale; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire Core; QOL = quality of life.
*p < 0.005
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Table 3.4 Themes Categorized by CLCSS Domains
Domain

Emerged themes

Stigma and shame

1) Not feeling guilty but regretting smoking cigarettes
2) Transferring the blame.

Social isolation

3) Feeling isolated because of physical limitations
4) Thinking lung cancer is a sentence to death

Discrimination

5) Putting trust in God, not worrying about being judged by
others
6) Lacking trust/fairness from insurance providers and employers

Smoking

7) People believing lung cancer is caused by smoking

Note. CLCSS = The Cataldo Lung Cancer Stigma Scale.
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Precursors
•
•

Perceptions of societal attitudes toward smoking and lung cancer
o Blame
o Shame
Self-knowledge of having a lung cancer diagnosis

Internalized Lung Cancer Stigma

Perceived Lung Cancer Stigma
(potential or actual)

Negative change in identity—stigma
and shame/smoking

Social disqualification—Social
isolation

Self-blame
Regret
Guilt

Limited opportunities—Discrimination

Depression

Responses
Quality of Life
Functionality
Role
Emotional
Health Status

Physical
Cognitive
Social
Physical Symptoms

Figure 3.1 Proposed Conceptual Model
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1.

I feel guilty because I have lung cancer.
What do you think about this statement?
How do you define “guilty” in this question?
Is the language understandable to you?
Do you think that you or someone with your condition may experience this?
Is there a better way to ask this question?

2.

People with lung cancer lose jobs when employers learn.
What are your thoughts about this statement?
Even if you are unaware of this happening to anyone with lung cancer, do you think it is possible?

3.

I work hard to keep my lung cancer a secret.
What do you think about this statement?
Is the language understandable to you?
Do you think that you or someone with your condition may experience this?
Is there a better way to ask this question?

4.

I feel I’m not as good as others because I have lung cancer.
What do you think about this statement?
What do you think this statement is saying about a person with lung cancer?

5.

People with lung cancer are treated like outcasts.
What do you think about this statement?
How would you define “outcast”?
Do you think anyone with lung cancer may feel like an outcast?

6.

Most people believe a person with lung cancer is dirty.
What do you think about this statement?
Can you tell me the meaning of “dirty” in this statement?
Do you feel or have any idea if others may feel this way?

7.

Having lung cancer makes me feel unclean.
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Tell me your thoughts about the words “makes me feel unclean.”
What does this mean to you?

8.

I feel set apart, isolated from the rest of the word.
What do you think about this statement?
What does “set apart” mean to you?
Do you feel that anyone with lung cancer may feel isolated?

9.

Having lung cancer makes me feel like I’m a bad person.
Tell me your thoughts about this statement?
Do you think others with lung cancer may experience this feeling?

10. Some people who know me have grown more distant.
What do you think about this statement?
What does “grown more distant” mean to you?

11. I worry about people discriminating against me.
What do you think about this statement?
What does “people discriminating against me” mean to you?
Why would someone with lung cancer feel this way?

12. Most are uncomfortable around someone with lung cancer.
What do you think about this statement?
What do you think “uncomfortable around someone with lung cancer” means?

13. I feel the need to hide the fact I have lung cancer.
What do you think about this statement?
Why would someone with lung cancer feel the need to hide this?

14. I worry that people may judge me when they learn I have lung cancer.
What do you think about this statement?
Why do you think someone with lung cancer would worry about being judged?

15. I was hurt how people reacted to learning I have lung cancer.

81

What do you think about this statement?
What reaction do you think this statement is talking about?

16. People I care about stopped calling after learning.
What do you think about this statement?
Do you have any idea why this would occur?

17. Some told me lung cancer is what I deserved for smoking.
What do you think about this statement?
What are your feelings about another person telling someone with lung cancer this?

18. People have physically backed away from me.
What do you think about this statement?
What do you think “physically backed away” means?

19. Some people think it is my fault I have lung cancer.
What do you think about this statement?

20. Stopped socializing with some due to their reactions.
What do you think about this statement?
What does stopping socializing mean to you?

21. Have lost friends by telling them I have lung cancer.
What do you think about this statement?
What are your feelings about lung cancer survivors losing friends after they find out about the
diagnosis?

22. People seem afraid of me because I have lung cancer.
What are your thoughts about people’s fear of someone with lung cancer?

23. Older people are less likely than younger people to be blamed for having lung
cancer.
What do you think about this statement?
Why would an older person have less blame than a younger person?

24. Health-care providers don’t take “smoker’s cough” seriously.
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What do you think about this statement?
What are your thoughts about a provider who doesn’t take this cough seriously?

25. People avoid you because lung cancer is associated with death.
What do you think about this statement?
Tell me what your feelings are about someone with lung cancer being alone.

26. My lung cancer diagnosis was delayed because my health-care provider did not
take my “smoker’s cough” seriously.
What do you think about this statement?
Do you think this could occur with a person with lung cancer, and if so, why?

27. I put off going to the doctor because I was afraid.
Please tell me how you feel about this statement.

28. Smokers could be refused treatment for lung cancer.
What do you think about this statement?
Tell me if you think that this could happen and why.

29. Others assume that a patient’s lung cancer was caused by smoking even if he
or she had stopped smoking years ago.
Please tell me your thoughts on this statement.

30. Others assume that a patient’s lung cancer was caused by smoking even if he
or she never smoked.
Tell me your thoughts on this statement.

31. Lung cancer is viewed as a self-inflicted disease.
What do you think about this statement?
Please tell me your meaning of self-inflicted.
Are there any more questions or areas that you think need to be asked?

Figure 3.2 Interview Guide
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CHAPTER 4:
STIGMA AMONG LUNG CANCER SURVIVORS IN SOUTH CAROLINA3

3

Webb, L. A., McDonnell, K. K., Adams, S. A., Davis, R. E., and Felder, T. M. To be submitted to the

European Journal of Oncology Nursing.
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Abstract
Purpose:
The study aimed to evaluate stigma among survivors of lung cancer. The Cataldo
Lung Cancer Stigma Scale (CLCSS) was used to assess stigma and its relationship with
race, depression, and quality of life (QOL) among survivors of lung cancer in South
Carolina.
Methods:
An adapted conceptual model derived from the CLCSS guided this descriptive
correlation study. Self-reported, written surveys measuring depression, QOL, and lung
cancer stigma, plus an investigator-developed demographic information form, were
administered to lung cancer survivors in South Carolina. Statistical analysis was
conducted to assess associations/relationships between stigma and depression, stigma and
QOL, and stigma and race, adjusting for demographic characteristics.
Results:
Participants (n = 56) included 30 Caucasian and 26 African American survivors of
lung cancer recruited from a cancer registry of an American College of Surgeons–
accredited program, a support club for survivors of lung cancer, and a private ambulatory
oncology practice, all near Columbia, South Carolina. Statistical analysis yielded (1) a
significant moderate positive association between depression and lung cancer stigma, (2)
a significant moderate negative association between QOL and lung cancer stigma, and (3)
significant relationships between race and lung cancer stigma.
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Conclusion:
Lung cancer stigma affects many aspects of lung cancer survivors’ lives. Healthcare professionals need to consider how this health-related stigma may further complicate
physical burdens, psychological distresses, and social challenges that accompany the
disease. Further inquiry and intervention development are needed to assist with
mitigating the negative effects of lung cancer stigma on survivors and their family
members and friends.
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Introduction
Lung cancer is the second most prevalent cancer in men and women and the
leading cause of cancer deaths in the United States (American Cancer Society [ACS],
2019). The lung cancer incidence and mortality rate have declined due to early screening
and improved treatment modalities (ACS, 2019; de Moor et al., 2013). However, the
disease remains a major concern because of its far-reaching negative effects on survivors’
overall quality of life (QOL) (Brown-Johnson et al., 2015; Chambers, Baade et al., 2015;
Chambers et al., 2012; Chapple, Ziebland, & McPherson, 2004; Gonzales & Jacobsen,
2012; Gonzalez et al., 2015; Hamann et al., 2014; Houlihan & Tyson, 2012). Survivors of
lung cancer, defined from the time of diagnosis to the end of life, experience significant
physical symptom burden, social challenges, and psychological distresses (Houlihan &
Tyson, 2012; Institute of Medicine [IOM] & National Research Council [NRC], 2006).
A challenge that survivors of lung cancer may face is stigma related to their
diagnosis. Stigma is an “undesirable stereotype leading people to reduce the bearer from
a whole and usual person to a tainted, discounted one” (Goffman, 1963). A health-related
stigma is the perception of a trait that is considered unfavorable and yields an adverse
result. In the case of lung cancer, the health-related stigma is the perception that an
individual with lung cancer has smoked or currently smokes cigarettes because tobacco is
the leading cause of lung cancer (Brown-Johnson, Brodsky, & Cataldo, 2014; Cataldo,
Jahan, & Pongquan, 2012; Cataldo, Slaughter, Jahan, Pongquan, & Hwang, 2011;
Chambers, Baade et al., 2015; Rauma, Sintonen, Räsänen, Salo, &Ilonen, 2015; Rowland
et al., 2016).
United States Surgeon General reports have documented strong evidence that
tobacco is an individual and environmental health hazard (U.S. Department of Health and
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Human Services Public Health Office of the Surgeon General [OSG], 2014). These
reports have heightened public awareness of the links between chronic and debilitating
disease processes and the behavior of cigarette smoking. Public awareness of the hazards
of smoking has led to the thought that this behavior is an unacceptable “choice” and no
longer a societal norm (Bayer, 2008). This leads to the ostracization of smokers and to
victim blaming of those who formerly or currently smoke despite its known hazards.
Lung cancer stigma’s layered effect on survivors impacts all aspects of their lives.
Survivors have reported feelings of social isolation and discrimination from friends and
family related to their diagnosis (Cataldo et al., 2011; Hamann et al., 2014; Shen et al.,
2015). Some survivors reported a reluctance to share their diagnosis and experiences with
others due to fear of their reactions (Webb & McDonnell, 2018). This alienation further
amplifies the influence of stigma and negatively affects psychological distress that they
may be experiencing. This effect of stigma also intensifies the burden of physical
symptoms such as shortness of breath, fatigue, insomnia, and pain—which, in turn,
negatively impact lung cancer survivors’ ability to deal with psychological and social
challenges in addition to adversely affecting their overall QOL (Gonzalez & Jacobsen,
2012). The lack of physical, mental, and social well-being majorly hampers survivors’
ability to manage physical symptom burden and to cope with social and mental
challenges—creating a vicious cycle. All of these factors ultimately influence overall
QOL and survival (Brown-Johnson et al., 2014; Cataldo et al., 2012; Cataldo et al., 2011;
Chambers, Baade et al., 2015; Rauma et al., 2015; Rowland et al., 2016).
In 2011, the Cataldo Lung Cancer Stigma Scale (CLCSS) became the first
psychometrically tested instrument specifically designed to assess lung cancer stigma.
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The original psychometric testing was conducted on an online sample primarily
consisting of Caucasian participants (86%); no African Americans were represented in
the testing (Cataldo et al., 2011). This original evaluation yielded great internal
consistency (a Cronbach’s alpha of .97), and construct validity was determined with
correlational analysis among similar variables: depression, QOL, anxiety, and social
isolation (Cataldo et al., 2011). Since 2011, the CLCSS has been used in more racially
diverse samples. However, the African American representation in those studies was still
low, thus limiting knowledge related to lung cancer stigma among this vulnerable
population of lung cancer survivors (Carter-Harris & Hall, 2014; Carter-Harris, Hermann,
Schreiber, Weaver, & Rawl, 2014; Chambers, Morris et al., 2015; Chambers, Baade et
al., 2015; Shen, Hamann, Thomas, & Ostroff, 2016).
Lung cancer mortality is highest among African Americans in comparison to their
Caucasian counterparts (ACS, 2019). Given this disparity, a sample with greater African
American representation would add to the knowledge of lung cancer stigma and overall
QOL for all lung cancer survivors. South Carolina, ranked 16th in lung cancer incidence,
has a larger age-adjusted incidence of lung cancer diagnoses in comparison to the
national rate; this disparity is especially great among males (84.4% in South Carolina vs.
71.3% nationally) compared to females (53.5% in South Carolina vs. 52.3% nationally)
(ACS, 2019). South Carolina is considered a rural state with a racial make-up of
approximately 68% non-Hispanic Caucasians, 28% non-Hispanic African Americans,
and 5% Hispanic Latinos (United States Census Bureau, 2017). The African American
age-adjusted incidence of lung cancer in South Carolina is 93.4% in comparison to a
79.3% incidence among Caucasians in the state. The death rate for African Americans
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with lung cancer in South Carolina is also higher than the death rate for Caucasians
(74.9% vs. 62.2%, respectively) (ACS, 2016). This disparate rate is multifactorial and
warrants inquiry to gain a better understanding of lung cancer survivorship among South
Carolinians and among African American lung cancer survivors.
To date, no study has examined lung cancer stigma among lung cancer survivors
in South Carolina. The purpose of this study is to evaluate stigma among lung cancer
survivors in the state, with equal representation of Caucasians and African Americans.
The aims of this study are to (1) evaluate the reliability and construct validity of the
CLCSS on a purposive sample of Caucasians and African Americans in South Carolina
with a history of lung cancer, stages Ia–IV; (2) calculate and compare levels of stigma,
depression, and QOL among demographic variables, gender, race, marital status,
educational attainment, income status, self-reported health status, and smoking status;
and (3) evaluate the relationship between race and lung cancer stigma, adjusting for
demographic variables.
The following hypotheses will be tested:
5. The CLCSS will demonstrate internal consistency among this population of
lung cancer survivors, with a Cronbach’s alpha of greater than 0.7.
6. There will be a statistically significant positive association between lung
cancer stigma and depressive symptoms.
7. There will be a statistically significant negative association between lung
cancer stigma and QOL.
8. There will be a statistically significant relationship between lung cancer
stigma and race, adjusting for demographic variables.
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Methods
Design
This study used descriptive and inferential analysis to analyze and quantify
relationships between independent demographic variables and lung cancer stigma,
depression, and QOL. To evaluate the linear relationship of stigma relative to dependent
variables, correlation analysis was used. To evaluate the relationship between lung cancer
stigma and race and the remainder of the demographic characteristics, a standard multiple
regression analysis was used.
Conceptual Framework
Based on the conceptual model of lung cancer stigma proposed by Cataldo et al.
(2011), this research will be guided by the principal investigator’s (PI’s) adapted model.
This model posits that lung cancer survivors perceive societal attitudes relative to
smoking and a lung cancer diagnosis. Survivors are aware of potential or actual behaviors
exhibited by others and by feelings that may occur because of this perception. This may
lead to feelings that negatively change their identity to one of stigma and shame. The
perceptions and feelings of survivors are associated with depression and QOL and
therefore affect survival rates. (See Figure 4.1.)
Design
This study used descriptive correlational analysis to analyze and quantify
relationships between independent demographic variables and lung cancer stigma,
depression, and QOL. To evaluate directional association relative to dependent variables,
correlation analysis was used. To evaluate the relationship between lung cancer stigma
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and the demographic characteristics, (race, marital status, smoking status, and selfreported health status), a standard multiple regression analysis was used.
Participant Selection, Recruitment, and Ethical Considerations
The institutional review boards (IRBs) of the University of South Carolina (USC)
and Palmetto Health (PH) in Columbia, South Carolina, approved this research.
Participants were eligible for the study if they were 21 years of age or older, had a
personal history of lung cancer, could speak and read English, and resided in South
Carolina. The primary recruitment method was an IRB-approved recruitment letter and
flyer describing the purpose and procedure of the study. The letter and flyer were mailed
over a 4-month period (May–August 2018) to 500 potential participants who were
identified by a cancer registry from a local cancer center accredited by the American
College of Surgeons. A follow-up telephone call was made to potential participants
within 1–2 weeks of mailing the printed materials. Potential participants had the option of
having the surveys mailed to them, administered by the PI via telephone, or administered
by the PI in person at a convenient location. A secondary recruitment method took place
at a meeting of the Breathe Easier Club, a support club for lung cancer survivors in
Columbia, South Carolina. This club provided the opportunity to meet potential
participants face-to-face. After the club meeting, potential participants were given the
opportunity to participate in the research. A third and final recruitment effort occurred at
a large, private ambulatory oncology practice in Columbia, South Carolina. IRBapproved flyers were placed in strategic areas at this practice, and face-to-face
introductions of the study were made to lung cancer survivors during their scheduled
appointments. Participants had the opportunity to participate upon completion of their
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appointment. Informed consent was obtained prior to participation, and upon completion
of the survey, each participant received an appreciation gift (a gift card to a local retail
store).
Instruments
Demographic Characteristics
The PI developed a demographic form to collect information about each
participant, including gender, age, annual household income, year of cancer diagnosis,
self-reported health status, smoking status, educational attainment, and employment data.
Stigma
The CLCSS is a 31-item, 4-point Likert scale that evaluates stigma. The original
psychometric testing was conducted by Cataldo et al (2011). Exploratory factor analysis
identified four domains: stigma and shame, social isolation, discrimination, and smoking.
Reliability was established by a coefficient alpha of 0.96 for the entire scale. Construct
validity was supported by association with the related constructs of self-esteem,
depression, social support, and social conflict. CLCSS scores range from 31 (low stigma)
to 124 (high stigma).
Depression
The Center for Epidemiologic Studies Depression Scale (CES-D) is a 20-item,
non-diagnostic, self-report scale. The instrument domains of depression include
depressed mood, feelings of guilt and worthlessness, feelings of helplessness and
hopelessness, psychomotor retardations, loss of appetite, and sleep disturbance (Radloff,
1977). This instrument has shown to be reliable across gender, race, and age, and it has a
high internal consistency, ranging from 0.85 to 0.90 (Radloff, 1977). Scores for this
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instrument range from 0 (indicating low depressive symptoms) to 60 (high depressive
symptoms).
Quality of Life
The European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire Core (EORTC QLQ-C30) measures QOL in individuals with a cancer
diagnosis. This scale was tested on lung cancer patients and yielded an acceptable
internal consistency of 0.70 with a sample size of 110. Criterion validity was supported
by correlation with clinical parameters that addressed all domains of the instrument
(Nicklasson & Bergman, 2007). A 13-item supplement specifically for lung cancer was
also used for this study. This study focused on the global health of the cancer survivor.
The score range was 0 (low global health) to 100 (high global health), where 56.6 is the
mean for lung cancer survivors.
Data Analysis
Data were analyzed using SPSS Statistics Version 25.0®. Descriptive statistics
were calculated to describe the sample. The CLCSS was reverse-scored and averaged.
The CES-D was scored and averaged according to the Center for Epidemiologic Studies’
guidelines. QOL was calculated by applying linear transformation to two global health
questions (representing participant QOL). Construct validity of the CLCSS was evaluated
using correlational analysis, which examined the linear relationship between lung cancer
stigma and depressive symptoms, and between lung cancer stigma and global health. A
general linear model analysis was conducted on lung cancer stigma and race, and the
remainder of the demographic characteristics. Factor and covariates model effects were
applied using the general linear model option in SPSS. Race was modeled as the primary
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effect with other demographic variables (individually), with lung cancer stigma as the
dependent variable. Using an alpha cutpoint of .05 from the bivariable models (race plus
one demographic variable at a time), we determined the covariates that may significantly
confound the relationship between race and stigma. The final model included race and
any other independent variable that demonstrated a significant relationship. Significance
in the final linear model was determined at p < .05.
Results
Participant Profile
The original sample included 62 individuals. Fifty out of the 62 participants were
recruited from the 500-member cancer registry direct mailing. Of the 500 direct mailings,
48 were returned and 178 of recipients were unable to be contacted. The remaining 12
participants were recruited from a meeting of the support club and the private oncology
practice. Six participants did not complete all of the requested survey material and
therefore were excluded from the data analysis. Of the 56 participants included in
analysis, 30 were Caucasians (54%) and 26 were African Americans (46%). Participant
ages ranged from 48 to 81 years with a mean of 67 (SD = 8.9). Over half of the sample
was married with some college education. Participants’ lung cancer stages ranged from
IA to IV, with over half of participants diagnosed within the past 2–3 years. Over 50%
rated their health as fair to poor. The sample included 43 former smokers, 7 never
smokers, and 6 current smokers (see Table 4.1).
Statistical Analysis
The CLCSS had a Cronbach’s alpha of .96, indicating very good internal
consistency. Correlational analysis displayed a statistically significant moderate positive
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association between stigma and depression (r = .345, p = .005) and a statistically
significant moderate negative association between stigma and QOL (r = -.303, p = .012).
This supports hypotheses 1, 2, and 3 (see Table 4.2). The average instrument scores were
as follows: lung cancer stigma, 51.38 + 16.32; depression, 15.84+ 10.22; and QOL, 62.68
+ 24.04. The average stigma score for Caucasian participants was 45.2 + 14.95, while for
African American participants the average was higher at 58.5 + 15.09. The independent ttest displayed a t value of -3.3 (p = .002), and an eta-squared of 16%, indicating that race
had a large effect on the mean stigma score. Race and gender were found to be
insignificantly related to overall depression and QOL (see Table 4.3). Participants who
were married displayed the lowest lung cancer stigma score on average (47.45 + 14.77);
by comparison, participants who were single had an average score of 68.2 + 14.97. This
finding was statistically significant, with a large effect related to marital status (p = .033,
η2 = 0.17). Marital status was also found to have a statistically significant relationship to
QOL. On average, participants who were single displayed a higher QOL (84.8 + 17.22)
than participants who were separated or divorced (50.45 + 23.69). This was shown to be
significant statistically, with a large effect attributed to marital status (p = .039, η2 = .17).
A generalized linear model was used to evaluate relationships among demographic
variables and lung cancer stigma. The final model consisted of race and income. Race
was found to have the strongest relationship to lung cancer stigma (p = .002) and income
demonstrated a relationship as well (p =.012). The estimated marginal mean for lung
cancer stigma for Caucasians was 48.05; for African Americans it was 60.03. (See Table
4.4.)
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Discussion
Evaluation of the CLCSS
In this study, the CLCSS was found to be a reliable and valid instrument among
this sample of lung cancer survivors. This 31-item instrument displayed a Cronbach’s
alpha of .96, which indicates good internal consistency, but also possible redundancy of
items. Carter-Harris and Hall (2014) developed a shortened version of the CLCSS. That
shorter version consisted of 21 items and displayed a Cronbach’s alpha of .93, indicating
very good internal consistency. Further investigation with this revised shortened
instrument is warranted and will continue to add to existing knowledge of lung cancer
stigma. It’s possible the shortened version will be more widely accepted in clinical
practice, as it may lessen the time and burden on survivors who complete it.
Relationship of Stigma to Depression and QOL
Lung cancer survivors experience great psychological distresses. This study
presents statistically significant findings of a moderate positive association with
depression. Depressive symptoms are prevalent among those living with lung cancer, and
depression is considered one of the most prominent psychological challenges for this
population (Brown-Johnson et al., 2014; Cataldo et al., 2012; Chambers et al., 2012;
Gonzalez & Jacobsen, 2012). In their study (N = 190), Cataldo et al. (2012) found that
increased depression was strongly associated with increased stigma, and that depression
was secondary to lung cancer stigma in impact on QOL. The two variables together
explain most of the variance with QOL. It is imperative to consider the interaction of
depression and stigma and how it may negatively impact social challenges and physical
symptoms, and thereby negatively affect QOL. This is especially important among
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African American cancer survivors because depression is frequently underdiagnosed,
misdiagnosed, and undertreated (Traeger, Cannon, Pirl, & Park, 2013). Untreated
depression is likely to further negatively impact all areas of life, potentially leading to an
inability to manage physical symptom burden and impeding the adoption of health
behaviors that can help improve overall QOL (McDonnell et al., 2019).
QOL is multifaceted and can have a direct influence on survival rates of cancer
survivors (Montazeri, 2009). This study demonstrated that lung cancer stigma has a
significantly moderate negative association with QOL. Chambers et al. (2012) found that
lung cancer stigma had an adverse effect on overall QOL in their systematic review.
Cataldo et al. (2012) had the same finding and indicated that stigma was a major
contributor to the variance of QOL. Given that survival rates are increasing among lung
cancer survivors, it is essential to consider the effect of lung cancer stigma, including the
effect it has on overall QOL along with daily challenges faced by these individuals.
African Americans on average experienced greater amounts of lung cancer stigma
and depression. Race significantly contributed to the variance in lung cancer stigma
experience. Interestingly, average overall QOL among African Americans was higher
than Caucasians in this study. This may be due, at least partly, to how QOL is calculated
with this particular instrument. The two weighted questions situated toward the end of the
instrument focus on overall health and overall QOL within the past week. This can create
a wide variation in the interpretation of the questions and thus in responses. African
American participants in this study gave a higher score for QOL despite their high
physical symptom burden in comparison to Caucasian participants. This was an
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unexpected finding. Further inquiry and exploration would generate better understanding
of this finding.
Demographic characteristics displayed some important associations with the three
dependent variables of stigma, depression, and QOL. As previously noted, race was
significantly associated with stigma and depression. However, other characteristics—
such as gender, educational attainment, employment status, and self-reported health
status—did not have a significant relationship to stigma, depression, or QOL. Although
there was no significant finding on smoking status and its relationship to stigma,
depression, or QOL, the never smokers in the study did, on average, display a lower lung
cancer stigma score in comparison to current and former smokers. This finding is similar
to those reported by Cataldo et al. (2012). Marital status displayed a significant
relationship with stigma, depression, and QOL in the correlational analysis. Participants
who were single displayed a higher level of stigma and QOL and a low level of
depressive symptoms, whereas divorced or separated participants reported a higher level
of depression. Interestingly, marital status was not related to stigma in the multiple
regression. Income level, on the other hand, was found to be significantly related to
stigma, almost equally to race. The Caucasians in this sample had an average stigma
score 10.8 points lower than the African Americans, indicating an overall lower
experience of stigma on average. Individuals in this sample whose income was above
$20,000 annually had a lower stigma score of 11.1 (on average) in comparison to
individuals earning under $20,000 annually, which is considered poverty level for a
household of three people (U.S. Department of Health and Human Services, 2019). A

99

lower socioeconomic status, race, education, and geographic location are variables that
indicate risk for cancer disparity (Dixit et al., 2016; Singh & Jemal, 2017).
For lung cancer survivors within our sample, race and income displayed a
relationship to lung cancer stigma. This is especially noteworthy due to the geographical
location in which the sample was obtained—South Carolina. This may be due in part to
the higher rates of smoking in the state, which may be linked to South Carolina’s relaxed
smoking policies. South Carolina is ranked 14th in the United States for prevalence of
smoking. Eighteen percent of both Caucasians and African Americans in the state smoke
cigarettes, while 30% of these individuals earn less than $25,000 yearly per household.
Among African Americans our sample exhibited higher average levels of lung cancer
stigma. African Americans historically have experienced negative associations with
discrimination, which substantially correlates with being stigmatized (Dixit et al., 2016).
The perception of stigma and discrimination can lead to depression, anxiety, social
isolation, delayed medical care, and altered patient-provider communication (BrownJohnson et al., 2014; Carter-Harris & Hall, 2014; Carter-Harris et al., 2014; Cataldo et al.,
2012; Chamber et al., 2015; Gonzalez & Jacobsen, 2012).
There are many research foci that lung cancer scientists need to consider. Further
research is particularly needed in the area of African American lung cancer survivors.
This study indicates that African Americans have higher levels of stigma. Additional
investigation of lung cancer stigma is needed in this population to assist with
development of interventions to alleviate this burden. Although it is well known that
socioeconomics is a factor in cancer disparity, multilevel interventions are needed to
assist with alleviating this disparity and lung cancer stigma among lung cancer survivors.
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Future research should focus on promoting healthy relationships and support
systems for lung cancer survivors. Additionally, consideration should be given to dyad
research and to developing interventions aimed at decreasing stigma and depression
while increasing overall QOL.
Conclusion
Lung cancer stigma affects many aspects of the lives of lung cancer survivors. It
is imperative that health-care professionals take into consideration factors, such as
socioeconomics and race, known to negatively influence cancer disparities among lung
cancer survivors. These factors and the effect that lung cancer stigma has on lung cancer
survivorship further complicates physical burdens, psychological distresses, and social
challenges.
Strengths and Limitations
African American lung cancer survivors experience a cancer disparity nationwide
and in the state of South Carolina. It is vital to increase participation of this vulnerable
population of cancer survivors in lung cancer studies. Carter-Harris et al. (2014)
conducted a lung cancer stigma study with only 17% African Americans while Shen et al.
(2016) had 14% representation of African Americans in their study. To the authors’
knowledge, this is the first study evaluating lung cancer stigma with nearly 50%
representation of African Americans among a population of lung cancer survivors. The
findings of this study confirm the known disparity. These findings will add to the
knowledge of lung cancer stigma for all lung cancer survivors but particularly African
Americans.

101

There are several limitations to this study. The sample size of 56 was small for a
descriptive correlational study. In addition, participants were recruited from a cancer
registry, a support club, and an ambulatory outpatient clinical practice in close proximity
to one another. Lung cancer survivors in this region may differ from other survivors in
other areas of the state, country, or internationally. Future studies should focus on
participants who are representative globally, with an emphasis on adequate representation
of African Americans and other vulnerable populations worldwide.
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Table 4.1 Sample Demographic Characteristics

Variable

Possible values

Self-reported results

Age
Male

M = 68.11/SD = 9.451
(Range: 45–89)
n = 19 (34%)

Female

n = 37 (66%)

Caucasian

n = 30 (54%)

African American

n = 26 (46%)

Marital

Single

n = 5 (9%)

status

Married

n = 31 (55%)

Separated/divorced

n = 11 (20%)

Widowed

n = 9 (16%)

Some high school

n = 7 (13%)

High school graduate or GED

n = 10 (18%)

Some college (13 years)

n = 22 (39%)

College (4 years or more)

n = 16 (29%)

Gender

Race

Education

Employment Employed for wages
status
Self-employed

Annual
household
income

n = 6 (11%)
n = 2 (4%)

Out of work < 1 year

n = 2 (4%)

Out of work > 1 year

n = 3 (5%)

Homemaker

n = 1 (2%)

Retired

n = 27 (48%)

Unable to work

n = 15 (27%)

< $5,000

n = 1 (2%)

$5,000–$9,999

n = 6 (11%)

$10,000–$19,999

n = 8 (14%)
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$20,000–$49,999

n = 23 (41%)

$50,000–$100,000

n = 9 (16%)

> $100,000

n = 6 (11%)

Not reported

n = 3 (5%)

Health

Excellent

n = 2 (4%)

status

Very good

n = 6 (11%)

Good

n = 18 (32%)

Fair

n = 21 (37%)

Poor

n = 9 (16%)

2016 or after

n = 30 (48%)

2015

n = 13 (21%)

2014

n = 2 (3%)

2013

n = 2 (3%)

2012

n = 1 (2%)

2011

n = 7 (11%)

2010 or prior

n = 7 (11%)

Smoking

Never smoker

n = 7 (12%)

status

Former smoker

n = 43 (77%)

Current smoker

n = 6 (11%)

Year of lung
cancer
diagnosis

Note. Some categories may not sum to 100% due to rounding.
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Table 4.2 Correlational Analysis with Pearson Product

Measure (Instrument)

Lung cancer
stigma
(CLCSS)

Lung cancer stigma
(CLCSS)
Depressive symptoms (CESD)

.345**

Global health/QOL (EORTC
QLQ-C30)

-.303*

Depressive
symptoms
(CES-D)

Global
health/ QOL
(EORTC
QLQ-C30)

.345**

-.303*
-.523**

-.523**

*p =.01
**p = .05
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Table 4.3 Independent T-test and One Way Anova
Mean/SD
Demographic
Variables
Overall
Race

Gender

Marital
status

Health
status

Smoking
status

Global Health/
QOL
(EORTC QLQC30)

Stigma
(CLCSS)
51.38/16.32

Depression
(CES-D)
16.3/11.8

62.68/24.03

45.2/14.96*

15.43/13.55

61.67/22.89

African American 58.5/15.10*

17.31/9.57

63.85/25.71

Male

51.36/17.30

13.53/8.67

59.53/28.55

Female

51.37/16.04

17.73/13

64.30/21.62

Single

68.2/14.97*

12.8/12.55

84.8/17.22*

Married

47.45/14.77

16.71/13.13

62.90/21.69

Separated/
divorced
Excellent

58.28/14.92

20.09/7.18*

50.45/23.69

50/26.87

13/9.90

58/11.31

Very good

46.17/13.15

9.33/8.57

88.5/8.52

Good

45.5/17.54

15.72/15.96

68.6/14.72

Fair

56.24/15.02

18.81/8.59

58.09/24.78

Poor

55.56/15.33

17/10.81

45.33/30.61

Current

52.67/22.21

17.17/9.95

59.5/27.91

Former

52.47/16.04

16.84/12.31

61.35/24.49

Never

43.57/12.2

12.28/10.61

73.57/16.10

Values

Caucasian

*p < .05
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Table 4.4 Lung Cancer Stigma: Adjusted Mean for Caucasians and African Americans
Independent Variable
Adjusted Mean
Race

Caucasian
48.05

African
American
60.03

p-value
.002

Note: Adjusted for gender, marital status, educational attainment, work status, selfreported health, time of diagnosis, and smoking status.

107

Precursors

•
•

Perceptions of societal attitudes toward smoking and lung cancer
o Blame
o Shame
Self-knowledge of having a lung cancer diagnosis

Internalized Lung Cancer Stigma

Perceived Lung Cancer Stigma
(potential or actual)

Negative change in identity—stigma
and shame/smoking

Social disqualification—Social
isolation

Self-blame
Regret
Guilt

Limited opportunities—Discrimination

Depression

Responses
Quality of Life
Functionality
Role
Emotional
Health Status

Physical
Cognitive
Social
Physical Symptoms

Figure 4.1 Proposed Lung Cancer Stigma Model
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CHAPTER 5: CONCLUSION
Overview of This Study
This study evaluated lung cancer stigma among survivors of lung cancers in South
Carolina. In comparison to previous studies evaluating lung cancer stigma, the difference
in this study was the sample—specifically, its racial composition. This study’s sample
consisted of 46% African Americans and 54% Caucasians—to date, this is the first study
of this kind to recruit an equal representation of Caucasian and African American
survivors of lung cancer. The rationale for recruiting this sample stems from the cancer
disparity experienced among African Americans living with lung cancer and the lack of
existing evidence relative to lung cancer stigma in this underrepresented population. To
address this disparity, equal percentages of African American and Caucasian participants
were warranted to facilitate comparisons and foster deeper understanding of lung cancer
stigma among survivors of lung cancer who are African Americans. The study also had
the effect of adding to the overall body of evidence related to survivors of lung cancer.
Lung cancer stigma impacts many different aspects of the life of a lung cancer
survivor. The proposed conceptual model of lung cancer stigma illustrates the
relationships among lung cancer stigma, depression, and overall quality of life (QOL).
Depression is a psychological challenge experienced by many survivors of cancer,
particularly lung cancer. Depression can be a reflective experience in stigma and
manifested as shame, isolation, and discrimination (Brown-Johnson, Brodsky, & Cataldo,
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2014). In addition to its intertwining relationship with stigma, underdiagnosed,
misdiagnosed, and undertreated depression can lead to adverse alterations in QOL
relative to physical and emotional manifestations. The associations among these
constructs are imperative to evaluate. The experience of lung cancer stigma can increase
depressive symptoms and decrease QOL, impacting survival rates among this population
of cancer survivors. Therefore, it was our purpose to evaluate stigma via the Cataldo
Lung Cancer Stigma Scale (CLCSS) and these related constructs among African
American and Caucasian South Carolinians living with lung cancer.
Quantitative and Qualitative Data: Chapter Three
A multiple-methods approach was used. The quantitative data of this study
provided important findings related to lung cancer stigma. Chapter three presents data
and results of the African American participants. This is the first study in which African
American survivors of lung cancers were evaluated relative to lung cancer stigma. This
study’s findings indicate that the CLCSS had excellent internal consistency reliability,
with a Cronbach’s alpha of .957. The CLCSS was the chosen instrument for evaluating
lung cancer stigma because it was adapted from Berger and colleagues’ (2001) HIV
Stigma Model, which was utilized among African Americans with HIV and had
demonstrated good internal consistency among this population (Buseh, Kelber, Hewitt,
Stevens, & Park, 2009). Construct validity was determined by the significant positive
association between lung cancer stigma and depression along with the negative
association between lung cancer stigma and QOL. These findings were consistent with
previous research findings with either no representation or a smaller representation of
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African Americans (Brown-Johnson et al., 2014; Cataldo, Jahan, & Pongquan, 2012;
Cataldo, Slaughter, Jahan, Pongquan, & Hwang, 2011).
These findings indicate that the CLCSS is a reliable instrument for evaluating
lung cancer stigma among both races. However, the qualitative data presented in this
study leaves to question if this is truly accurate. There were two items in the CLCSS that
were misinterpreted; both related to the intended meaning, thereby identifying that
cultural considerations influence the accuracy of instruments and the constructs they
measure. In view of the two misinterpreted items for this sample of African American
survivors of lung cancer, we must consider that this may extend beyond the two items
when given the opportunity to evaluate other African American survivors. Careful
attention is warranted when utilizing instruments to evaluate cultures for both clinical and
research settings.
Evaluating the qualitative data generated a deeper understanding of the experience
of lung cancer stigma from the perspective of African Americans and contributed to the
rigor and robustness of the data (Creswell, 2013). The African Americans in this study
reported a moderately high level of stigma and depression. They also reported a higher
QOL than expected. The semi-structured interviews elicited data showing that, within
this sample of African American survivors of lung cancer, despite significant physical
symptom burden and depressive symptoms, these participants were thankful to have the
ability to live and fight for another day and therefore felt their QOL was adequate. They
also expressed that judgement from others did not have a bearing on how they felt about
themselves even though there were regrets about their health behavior decisions. This
response is positive and an adaptive response to perceived stigma of shame and blame
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(Hamann, et al., 2014). This is essential evidence regarding coping with lung cancer
stigma.
Despite that the African Americans reported a higher QOL, the survival rates
remain dismally lower for this population (American Cancer Society [ACS], 2016).
Disparity among African American survivors of lung cancer can be attributed to
diagnosis at later stages of cancer with metastasis, higher symptom burden, and higher
levels of depressive symptoms (ACS, 2016; Traeger, Cannon, Pirl, & Park, 2013).
Lathan, Waldman, Browning, Gagne, and Emmons (2015) reported in their qualitative
study that African American survivors of lung cancer expressed that the disparity they
experience is a result of race and quality of care. Interestingly, participants in this study
expressed their lack of trust and lack of fair treatment from insurance companies and
employers. They expressed that both entities’ treatment stemmed from financial gain
and/or loss. Lung cancer stigma can be reflective of perceived discrimination not only for
society but also from established entities such as insurance providers and employers. This
was an interesting finding among these participants.
Social isolation was described by many participants. This isolation was associated
with physical symptoms and depressive symptoms. So despite the higher level of QOL,
this population of survivors of lung cancer experience lung cancer stigma as indicated by
discrimination, social isolation, and the responsibility of cigarette smoking. However, the
shame associated with stigma was not indicated through the qualitative data.
Quantitative Data: Chapter Four
The quantitative data of the study evaluated the entire sample in chapter 4.
Internal consistency reliability for the entire sample was .96, which was also excellent.
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The same finding relative to construct validity was reported with the entire sample, for
both African Americans and Caucasians survivors of lung cancer. The levels of stigma,
depression, and QOL were important to evaluate for comparison to give indication of
difference and insight on the possible effect of the association of these constructs. African
Americans reported experiencing lung cancer stigma at a higher level than their
Caucasian counterparts. Depression also was reported at a higher level among African
American then Caucasians. Surprisingly, African Americans reported a higher QOL than
Caucasians in the study. The latter was an unexpected finding. However, the qualitative
part of the study, in chapter 3, assisted with understanding this finding. Another
important notable finding was that race was significantly related to lung cancer stigma
and that African Americans had a higher adjusted level of stigma than Caucasians. In
fact, the findings indicated that, after adjusting for demographic characteristics
(educational attainment, gender, smoking status, work status, time of diagnosis, marital
status, and self-reported health status), African Americans’ stigma scores were an
average of 10 to 11 points higher than those of Caucasians. This was a statistically
significant finding. Income was also a statistically significant factor, with lower annual
household incomes associated with higher levels of stigma experienced by the lung
cancer survivors. This addresses a gap in the literature and will add to the body of
knowledge of lung cancer.
Clinical Implications
Survivors of lung cancer live with tremendous physical symptom burden and
psychological distress, which lead to social isolation and lower overall QOL
(encompassing physical, mental, and social well-being). It is difficult to differentiate
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causation of these challenges due to their interrelation. It is important, however, that
health professionals acknowledge and have awareness of the presence of lung cancer
stigma and of its negative ramifications for overall QOL. A holistic assessment approach
including physical, psychological, and social well-being of survivors of lung cancer is
warranted to develop appropriate individualized care planning and treatment. In addition,
survivors should be assessed for psychological distresses, such as depression and anxiety
stemming from socioeconomic-related needs. Doing so should assist with further
investigation into the relationships of these distresses with stigma, and their ability to
compound existing psychological and social challenges, thus increasing physical
symptom burden to perpetuate a vicious cycle.
Research Implications
Despite improvements in public awareness of lung cancer, stigma persists. Future
research focuses should include public perception of lung cancer stigma and
incorporation of tailored public awareness of lung cancer stigma. As evidence has
indicated, it is difficult to change public perception; myriad efforts and many years may
be necessary (Public Agenda, 2016). Health communication research can direct these
efforts and propel them forward. Just as important, research should be pursued that
focuses on developing interventions that will decrease the negative effects of stigma on
those living with lung cancer. Disparities related to lung cancer warrant further
investigation, including evaluation of depression among all living with lung cancer,
particularly African Americans. Specifically, investigation should focus on medical
providers’ recognition and treatment of depressive symptoms in this vulnerable
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population, as well as on health communication with this group concerning depression
education.
Conclusion
The major strength of this research is that it generated new evidence related to
lung cancer survivors in South Carolina and contributed to the body of knowledge about
African American lung cancer survivors. As described earlier, a second strength was the
nearly equal representation of African Americans in the study. The third strength was the
multiple-method approach, which provided rich qualitative data that deepened
understanding of lung cancer stigma and validated the quantitative data. However, the
sample size was smaller than desired and represented only a small region of the United
States, thereby limiting the ability to generalize the findings. The researchers involved in
this study desire to continue investigating survivors of lung cancer among all vulnerable
populations and throughout all regions of the United States, in both rural and
metropolitan areas. In addition to these future research goals, investigating cultural
considerations such as understanding and interpretation of the CLCSS is warranted
among a geographically diverse group of African Americans survivors of lung cancer.
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APPENDIX A:
THE CATALDO LUNG CANCER STIGMA SCALE (CLCSS), FULL AND SHORT
VERSIONS, PLUS PERMISSION TO USE
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Cataldo Lung Cancer Stigma Scale
Instructions: Below is a list of statements dealing with your general feelings about
yourself. If you strongly agree, circle SA. If you agree with the statement, circle A. If
you disagree, circle D. If you strongly disagree, circle SD.

1.

2.

3.

4.

5.

6.

7.

8.
9.

10.

Strongly
Agree

Agree

Disagree

Strongly
Disagree

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

I feel set apart, isolated
from the rest of the word.

1

2

3

4

Having lung cancer makes
me feel like I’m a bad
person.

1

2

3

4

1

2

3

4

I feel guilty because I have
lung cancer.
People with lung cancer
lose jobs when employers
learn.
I work hard to keep my lung
cancer a secret.
I feel I’m not as good as
others because I have lung
cancer.
People with lung cancer are
treated like outcasts.
Most people believe a
person with lung cancer is
dirty.
Having lung cancer makes
me feel unclean.

Some people who know
have grown more distant.

130

11.

12.

13.

14.

15.

16.

17.

18.

19.

20.

21.

22.

I worry about people
discriminating against me.

1

2

3

4

1

2

3

4

1

2

3

4

I worry that people may
judge me when they learn I
have lung cancer.

1

2

3

4

I was hurt how people
reacted to learning I have
lung cancer.

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

Most are uncomfortable
around someone with lung
cancer.
I feel the need to hide the
fact I have lung cancer.

People I care about stopped
calling after learning.
Some told me lung cancer is
what I deserved for
smoking.
People have physically
backed away from me.
Some people think it is my
fault I have lung cancer.
Stopped socializing with
some due to their reactions.
Have lost friends by telling
them I have lung cancer.
People seem afraid of me
because I have lung cancer.
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23.

24.

25.

26.

27.

28.

29.

30.

31.

Older people are less likely
than young people to be
blamed for having lung
cancer.

1

2

3

4

Healthcare providers don’t
take “smoker’s cough
seriously”.

1

2

3

4

People avoid you because
lung cancer is associated
with death.

1

2

3

4

1

2

3

4

1

2

3

4

1

2

3

4

Others assume that a
patient’s lung cancer was
caused by smoking even if
he or she had stopped
smoking years ago.

1

2

3

4

Others assume that a
patient’s lung cancer was
caused by smoking even if
he or she never smoked.

1

2

3

4

1

2

3

4

My lung cancer diagnosis
was delayed because my
health care provider did not
take my “smoker’s cough”
seriously.
I put off going to the doctor
because I was afraid.
Smokers could be refused
treatment for lung cancer.

Lung cancer is viewed as a
self-inflicted disease.

Thank you for completing the Lung Cancer Stigma Scale.
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11-Item Scale
Below is a list of statements dealing with your general feelings about yourself. If you
strongly agree, circle SA. If you agree with the statement, circle A. If you disagree,
circle D. If you strongly disagree, circle SD.
Strongly
Agree

Agree

Disagree

Strongly
Disagree

1.

I feel guilty because I have
lung cancer.

1

2

3

4

2.

Some people assume that a
person’s lung cancer was
caused by smoking, even if
he or she never smoked.

1

2

3

4

3.

I try to keep my lung cancer
a secret.

1

2

3

4

4.

Some people are
uncomfortable around me
because they associate lung
cancer with death.

1

2

3

4

I worry that people may
judge me because I have
lung cancer.

1

2

3

4

6.

Some people believe lung
cancer is what I deserve.

1

2

3

4

7.

Some people act like it is
my fault I have lung cancer.

1

2

3

4

8.

I stopped socializing with
some people because of
their reactions to my lung
cancer diagnosis.

1

2

3

4

9.

I worry about people
discriminating against me.

1

2

3

4

10.

Some health care providers
would treat me better if I
had a different kind of
cancer.

1

2

3

4

5.
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11.

Lung cancer is viewed as a
self-inflicted disease.

1
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2

3

4
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APPENDIX B:
THE CENTER FOR EPIDEMIOLOGIC STUDIES DEPRESSION SCALE (CES-D)
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APPENDIX C:
THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF
CANCER QUALITY OF LIFE QUESTIONNAIRE CORE 30 (EORTC QLQ-30)
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APPENDIX D:
DEMOGRAPHIC INFORMATION FORM
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Information Form
Study ID #:__________
Date: ______________

Instructions: Please provide some background information about yourself by circling the
best response or filling in the blank. Thank you.

1. What year were you born?

________________

2. Are you male or female? ___________________
3. What is your race ?
A.
B.
C.
D.
E.
F.
G.

Caucasian
Black or Afro-American
Latino (Puerto Rican, Cuban, Dominican etc.)
West Indian (Haitian, Jamaican etc.)
Oriental or Asian American
Native American
Other

4. What is your marital status?
A. Single (never married)
B. Seperated or divorced (not living with a husband/wife)
C. Married (living with a husband/wife/significant friend)
D. Widowed
5. What is the highest grade or year of school you complete?
A. Never attended school or only attended kindergarten
B. Grades 1 through 8 (Elementary)
C. Grades 9 through 11 (Some high school)
D. Grade 12 or GEC (High school graduate)
E. College 1 year to 3 years (Some college or technical school)
F. College 4 years or more (College graduate)
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6. Are currently . . .
A. Employed for wages
B. Self-employed
C. Out of work for 1 year or more
D. Out of work for less than 1 year
E. A Homemaker
F. A Student
G. Retired
H. Unable to work
7. What is the annual income of your household?
A. $4,999 or less
B. $5,000-$9,999
C. $10,000-$19,999
D. $20,000-$49,000
E. $50,000-$99,000
F. $100,000 or more
8. Would you say that in general your health is:
A. Excellent
B. Very good
C. Good
D. Fair
E. Poor
9. In what year were you first told that you had lung cancer?
A. 2016
B. 2015
C. 2014
D. 2013
E. 2012
F. 2011
G. 2010
10. Have you smoked at least 100 cigarettes in your entire life? (5 packs = 100
cigarettes)
A. Yes
B. No
C. Not at all
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11. Do you now smoke cigarettes?
A. Everyday
B. Some days
C. Not at all
12. For how many years did you smoke regularly? _______________
13. If you do not currently smoke cigarettes but did in the past, how long has it been
since you last smoke regularly? (example every day or some days)
A.
B.
C.
D.
E.
F.
G.
H.
I.

Within the past month (0-1 month ago)
Within the past 3 months (1-3 months ago)
Within the past 6 months (3-6 months ago)
Within the past year (6-12 months ago)
Within the past 5 years (1-5 years ago)
Within the past 15 years (5-15 years ago)
More than 15 or more years ago
Don’t know/Not sure
Never smoked regularly

14. On average, about how many cigarettes a day do or did you smoke? (1 pack = 20
cigarettes) __________cigarettes.
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PERMISSION TO REPRINT PAPER FOR CHAPTER 2
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